<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Desmopressin for treating nocturia in men - Han, J - 2017 | Cochrane Library</title> <meta content="Desmopressin for treating nocturia in men - Han, J - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012059.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Desmopressin for treating nocturia in men - Han, J - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012059.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012059.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Desmopressin for treating nocturia in men" name="citation_title"/> <meta content="Julia Han" name="citation_author"/> <meta content="University of Florida" name="citation_author_institution"/> <meta content="Jae Hung Jung" name="citation_author"/> <meta content="Yonsei University Wonju College of Medicine" name="citation_author_institution"/> <meta content="Caitlin J Bakker" name="citation_author"/> <meta content="University of Minnesota" name="citation_author_institution"/> <meta content="Mark H Ebell" name="citation_author"/> <meta content="University of Georgia" name="citation_author_institution"/> <meta content="Philipp Dahm" name="citation_author"/> <meta content="pdahm@umn.edu" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD012059.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/10/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012059.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012059.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012059.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenergic alpha‐Antagonists [therapeutic use]; Antidiuretic Agents [adverse effects, *therapeutic use]; Cholinergic Antagonists [therapeutic use]; Deamino Arginine Vasopressin [adverse effects, *therapeutic use]; Drug Therapy, Combination; Nocturia [*drug therapy]; Quality of Life; Randomized Controlled Trials as Topic; Withholding Treatment" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012059.pub2&amp;doi=10.1002/14651858.CD012059.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="z6k50IFd";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012059\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012059\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012059\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012059\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","de","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012059.pub2",title:"Desmopressin for treating nocturia in men",firstPublishedDate:"Oct 21, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Urology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=z6k50IFd&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012059.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012059.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012059.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012059.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012059.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012059.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012059.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012059.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012059.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012059.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3843 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012059.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/full#CD012059-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/full#CD012059-sec-0200"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/full#CD012059-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/full#CD012059-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/full#CD012059-sec-0037"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/full#CD012059-sec-0038"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/full#CD012059-sec-0075"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/full#CD012059-sec-0188"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/appendices#CD012059-sec-0205"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/table_n/CD012059StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/table_n/CD012059StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Desmopressin for treating nocturia in men</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/information#CD012059-cr-0002">Julia Han</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/information#CD012059-cr-0003">Jae Hung Jung</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/information#CD012059-cr-0004">Caitlin J Bakker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/information#CD012059-cr-0005">Mark H Ebell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012059.pub2/information#CD012059-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Philipp Dahm</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/information/en#CD012059-sec-0224">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 October 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012059.pub2">https://doi.org/10.1002/14651858.CD012059.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012059-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012059-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012059-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012059-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012059-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012059-abs-0001" lang="en"> <section id="CD012059-sec-0001"> <h3 class="title" id="CD012059-sec-0001">Background</h3> <p>Nocturia is the bothersome symptom of awakening one or more times per night to void. Desmopressin is a commonly used medication for treating nocturia. </p> </section> <section id="CD012059-sec-0002"> <h3 class="title" id="CD012059-sec-0002">Objectives</h3> <p>To assess the effects of desmopressin as compared to other interventions in the treatment of nocturia in men. </p> </section> <section id="CD012059-sec-0003"> <h3 class="title" id="CD012059-sec-0003">Search methods</h3> <p>We performed a comprehensive search of the medical literature with no restrictions on the language of publication or publication status. The date of the latest search of all databases was August 2017. </p> </section> <section id="CD012059-sec-0004"> <h3 class="title" id="CD012059-sec-0004">Selection criteria</h3> <p>We included randomised or quasi‐randomised trials. Inclusion criteria were men with nocturia defined as one or more voids per night. We excluded trials of children or adults with primary or secondary enuresis or underlying distinct disorders. </p> </section> <section id="CD012059-sec-0005"> <h3 class="title" id="CD012059-sec-0005">Data collection and analysis</h3> <p>Two review authors independently classified studies and abstracted data from the included studies. We performed statistical analyses using a random‐effects model and interpreted data according to the <i>Cochrane Handbook for Systematic Reviews of Interventions.</i> We compared desmopressin with placebo, behavioural modification, alpha‐blockers, in combination with alpha‐blockers against alpha‐blockers alone, and in combination with alpha‐blocker against alpha‐blocker plus anticholinergic. Our outcomes were mean number of voids, quality of life, adverse events, and sleep disturbance. </p> </section> <section id="CD012059-sec-0006"> <h3 class="title" id="CD012059-sec-0006">Main results</h3> <p>We included 14 studies with 2966 randomised men across five comparisons. The studies recruited from urology outpatients clinics and defined nocturia as two or more voids per night. The average age of study participants ranged between 57 and 74 years. </p> <p><b>Desmopressin versus placebo:</b> based on short‐term follow‐up (up to three months), desmopressin may result in a small, possibly unimportant effect on the number of nocturnal voids (mean difference (MD) ‐0.61, 95% confidence interval (CI) ‐0.96 to ‐0.27; low‐quality evidence). We are uncertain about the effect of desmopressin on major adverse events at short‐term follow‐up (risk ratio (RR) 0.97, 95% CI 0.10 to 9.03; very low‐quality evidence). For intermediate‐term follow‐up (three to 12 months), desmopressin may reduce the number of nocturnal voids in an appreciable number of men (MD ‐0.85, 95% CI ‐1.17 to ‐0.53; low‐quality evidence). There was one major adverse event in the desmopressin group at intermediate‐term follow‐up in one trial of 115 men (RR 3.05, 95% CI 0.13 to 73.39 for both outcomes; low‐quality evidence). We found no evidence on quality of life. Subgroup analyses suggest a larger effect on nocturnal voiding with oral, higher‐dose formulations of desmopressin and in men with documented nocturnal polyuria. </p> <p><b>Desmopressin versus behaviour modification:</b> there were no data regarding the effect on the number of nocturnal voids, quality of life, or major adverse events. </p> <p><b>Desmopressin versus alpha‐blocker:</b> based on short‐term follow‐up in one small trial, desmopressin likely has a similar effect on the number of nocturnal voids (MD 0.30, 95% CI ‐0.20 to 0.80; moderate‐quality evidence) and quality of life measured on the International Prostate Symptom Score (IPSS) scale (MD 0.00, 95% CI ‐0.35 to 0.35; moderate‐quality evidence). There were no major adverse events in either group. </p> <p><b>Desmopressin plus alpha‐blocker versus alpha‐blocker alone:</b> based on short‐term follow‐up, combination therapy likely results in a small, unimportant effect on the number of nocturnal voids (MD ‐0.47, 95% CI ‐0.73 to ‐0.21; moderate‐quality evidence) and quality of life (MD ‐0.29, 95% CI ‐0.51 to ‐0.07; moderate‐quality evidence). The risk of major adverse events may be similar (0.5% versus 0.3%; RR 0.30, 95% CI 0.01 to 7.32; low‐quality evidence). </p> <p><b>Desmopressin plus alpha‐blocker versus alpha‐blocker plus an anticholinergic:</b> based on short‐term follow‐up, combination therapy likely results in little or no difference in the number of nocturnal voids (MD ‐0.43, 95% CI ‐0.97 to 0.11; moderate‐quality evidence). We found no evidence on quality of life or sleep duration. There were no major adverse events in either study group. </p> </section> <section id="CD012059-sec-0007"> <h3 class="title" id="CD012059-sec-0007">Authors' conclusions</h3> <p>Desmopressin may reduce the number of nocturnal voids by a small amount compared to placebo in intermediate‐term (three to 12 months) follow‐up without increasing major adverse events. We found insufficient evidence to determine the effects of desmopressin when compared with behaviour modification. The effect on the number of nocturnal voids in the short term is likely to be similar to that of alpha‐blockers, with very infrequent major adverse events. There appears to be little added benefit in the combined use of desmopressin with an alpha‐blocker. The findings of this review were limited by short‐term follow‐up, study limitations, and imprecision. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012059-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012059-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012059-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012059-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012059-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012059-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012059-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012059-abs-0004" lang="en"> <h3>Desmopressin for treating nocturia in men with lower urinary tract symptoms</h3> <p><b>Review question</b> </p> <p>Is desmopressin effective for treating nocturia in men?</p> <p><b>Background</b> </p> <p>Nocturia is the bothersome symptom of waking one or more times per night to pass urine. It is common in older men. More than half of men older than 70 years of age have nocturia, and there are many reasons for this. Desmopressin is a drug that regulates urine volume and concentration in the body. It is also used to treat nocturia. </p> <p><b>Study characteristics</b> </p> <p>The search is up‐to‐date to 1 August 2017. We identified 14 clinical trials including 2966 men. We compared desmopressin alone or in combination with other medicines used for urinary problems (such as alpha‐blockers or anticholinergics) against placebo (pretend treatment), behaviour changes, or medicines used for urinary problems alone or in combination. Most of the included studies enrolled only older men. </p> <p><b>Key results</b> </p> <p>Treatment with desmopressin for three to 12 months may reduce how often men urinate at night in a small number of men compared to placebo. Serious side effects were not increased. We do not know how the use of desmopressin compares to changes in behaviour. The effect of desmopressin on how often men urinate at night is likely to be similar to that of alpha‐blockers when given for up to three months (i.e. short‐term treatment) without major side effects. Adding desmopressin to an alpha‐blocker seems to work little better than an alpha‐blocker alone or an alpha‐blocker combined with an anticholinergic. </p> <p><b>Quality of the evidence</b> </p> <p>We rated the quality of the evidence to be low in most cases, meaning that we cannot fully trust the results. The included studies were poorly designed, small, and only followed people for a short time (usually three months or less). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012059-sec-0200" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012059-sec-0200"></div> <h3 class="title" id="CD012059-sec-0201">Implications for practice</h3> <section id="CD012059-sec-0201"> <p>The findings of this Cochrane Review showed that desmopressin was associated with similar or small, unimportant effects on the number of nocturnal voids, quality of life, and major adverse events across the included comparisons. </p> </section> <h3 class="title" id="CD012059-sec-0202">Implications for research</h3> <section id="CD012059-sec-0202"> <p>Given the low‐quality evidence for most of the reported analyses, there is a need for additional research with regard to drug effectiveness and safety. </p> <p> <ul id="CD012059-list-0026"> <li> <p>Future trials should be conducted according to higher methodological standards with regard to allocation concealment and blinding in order to minimise concerns about selection, performance, and detection bias. </p> </li> <li> <p>Trials should focus on long‐term, patient‐important outcomes and include quality of life as an outcome. </p> </li> <li> <p>Study data, especially for adverse events, need to be fully available to the research community. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012059-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012059-sec-0022"></div> <div class="table" id="CD012059-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Desmopressin versus placebo for men with nocturia (short term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> men with nocturia </p> <p><b>Setting:</b> likely outpatient </p> <p><b>Intervention:</b> desmopressin </p> <p><b>Control:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk difference with desmopressin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of nocturnal voids</b><br/> assessed with: voiding diary<br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1982<br/> (6 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean number of nocturnal voids ranged from 1.9 to 4.57.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.61 lower<br/> (0.96 lower to 0.27 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major adverse events</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>536<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/> (0.10 to 9.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 fewer per 1000<br/> (26 fewer to 233 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of first sleep episode</b><br/> assessed with: voiding diary<br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>652<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean duration of first sleep episode ranged from 26.21 to 174 minutes.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 54.61 minutes higher<br/> (13.97 higher to 95.25 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first void</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>383<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean time to first void was 72.9 minutes.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 40.8 minutes higher<br/> (17.07 higher to 64.53 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Minor adverse event</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>594<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.87<br/> (0.67 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 fewer per 1000<br/> (33 more to 85 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawal due to adverse event</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>614<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.10<br/> (0.56 to 2.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 more per 1000<br/> (21 fewer to 56 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for study limitations: unclear or high risk of bias for one or more domains in at least 50% of the studies.<br/> <sup>2</sup>Downgraded by one level for inconsistency: substantial heterogeneity among studies.<br/> <sup>3</sup>Downgraded by one level for imprecision: confidence interval was wide or crossed assumed threshold of clinically important difference (or both). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012059-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Desmopressin versus placebo for men with nocturia (intermediate term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> men with nocturia </p> <p><b>Setting:</b> likely outpatient </p> <p><b>Intervention:</b> desmopressin </p> <p><b>Control:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk difference with desmopressin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of nocturnal voids</b><br/> assessed with: voiding diary<br/> follow‐up: range 3 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>115<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of nocturnal voids was 4.14 voids.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.85 voids fewer<br/> (1.17 fewer to 0.53 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major adverse events</b><br/> follow‐up: range 3 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>115<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.05<br/> (0.13 to 73.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of first sleep episode</b><br/> assessed with: voiding diary<br/> follow‐up: range 3 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>115<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean duration of first sleep episode was 101.6 minutes.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 18.4 minutes higher<br/> (11.6 higher to 25.2 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first void</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Minor adverse events</b><br/> follow‐up: range 3 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>115<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/> (0.49 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>328 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 fewer per 1000<br/> (167 fewer to 161 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawal due to adverse event</b><br/> follow‐up: range 3 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>115<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.05<br/> (0.13 to 73.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for study limitations: unclear risk of bias for one or more domains in the included study.<br/> <sup>2</sup>Downgraded by one level for imprecision: confidence interval was wide or crossed assumed threshold of clinically important difference (or both).<br/> <sup>3</sup>Only one event in desmopressin group. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012059-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Desmopressin versus behaviour modifications for men with nocturia (short term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> men with nocturia </p> <p><b>Setting:</b> likely outpatient </p> <p><b>Intervention:</b> desmopressin </p> <p><b>Control:</b> fluid restriction during nighttime </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with behaviour modification</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk difference with desmopressin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of nocturnal voids</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major adverse events</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of first sleep episode</b><br/> assessed with: not reported<br/> follow‐up: mean 2 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean duration of first sleep episode was 150 minutes.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 90 minutes higher<br/> (1.95 higher to 178.05 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first void</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor adverse events</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment withdrawal due to adverse event</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for study limitations: unclear risk of bias in almost all domains in the included study.<br/> <sup>2</sup>Downgraded by one level for imprecision: confidence interval crossed assumed threshold of clinically important difference. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012059-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Desmopressin versus alpha‐blocker for men with nocturia (short term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> men with nocturia </p> <p><b>Setting:</b> likely outpatient </p> <p><b>Intervention:</b> desmopressin </p> <p><b>Control:</b> alpha‐blocker </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with alpha‐blocker</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk difference with desmopressin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of nocturnal voids</b><br/> assessed with: voiding diary<br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of nocturnal voids was 1.2 voids.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.3 voids more<br/> (0.2 fewer to 0.8 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><br/> assessed with: IPSS and N‐QoL<br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean quality of life was 1.8 bothersome.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0<br/> (0.35 lower to 0.35 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major adverse events</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of first sleep episode</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first void</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Minor adverse events</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/> (0.07 to 15.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 more per 1000<br/> (58 fewer to 911 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawal due to adverse event</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IPSS:</b> International Prostate Symptom Score; <b>MD:</b> mean difference; <b>N‐QoL:</b> Nocturia‐Quality of Life questionnaire; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for study limitations: unclear or high risk of bias for one or more domains in the included study.<br/> <sup>2</sup>Downgraded by one level for imprecision: no event in either group.<br/> <sup>3</sup>Downgraded by two levels for imprecision: confidence interval was wide and crossed assumed threshold of clinically important difference. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012059-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Desmopressin plus alpha‐blocker versus alpha‐blocker for men with nocturia (short term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> men with nocturia </p> <p><b>Setting:</b> likely outpatient </p> <p><b>Intervention:</b> desmopressin + alpha‐blocker </p> <p><b>Control:</b> alpha‐blocker alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with alpha‐blocker</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk difference with desmopressin + alpha‐blocker</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of nocturnal voids</b> </p> <p>assessed with: voiding diary<br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>341<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of nocturnal voids ranged from 1.68 to 2.6.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.47 voids fewer<br/> (0.73 fewer to 0.21 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p>assessed with: IPSS and N‐QoL<br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>341<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean quality of life ranged from 1.53 to 4.4.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.29 lower<br/> (0.51 lower to 0.07 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major adverse events</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>402<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.30<br/> (0.01 to 7.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 fewer per 1000<br/> (5 fewer to 32 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of first sleep episode</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first void</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Minor adverse events</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>402<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.60<br/> (0.15 to 16.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 more per 1000<br/> (68 fewer to 1000 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawal due to adverse event</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>402<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.84<br/> (0.46 to 17.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 more per 1000<br/> (3 fewer to 83 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IPSS:</b> International Prostate Symptom Score; <b>MD:</b> mean difference; <b>N‐QoL:</b> Nocturia‐Quality of Life questionnaire; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for study limitations: unclear or high risk of bias for one or more domains among the included studies.<br/> <sup>2</sup>Downgraded by one level for imprecision: no event or very rare event resulting in wide confidence interval.<br/> <sup>3</sup>Downgraded by two level for imprecision: confidence interval was wide and crossed assumed threshold of clinically important difference. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012059-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Desmopressin plus alpha‐blocker versus alpha‐blocker plus anticholinergic for men with nocturia (short term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> men with nocturia </p> <p><b>Setting:</b> likely outpatient </p> <p><b>Intervention:</b> desmopressin + alpha‐blocker </p> <p><b>Control:</b> anticholinergic + alpha‐blocker </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with alpha‐blocker + anticholinergic</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk difference with desmopressin + alpha‐blocker</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of nocturnal voids</b><br/> assessed with: voiding diary<br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>405<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of nocturnal voids was 6.97 voids.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.43 voids fewer<br/> (0.97 fewer to 0.11 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major adverse events</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>427<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of first sleep episode</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first void</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Minor adverse events</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>427<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.22<br/> (0.05 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 fewer per 1000<br/> (43 fewer to 1 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawal due to adverse event</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>427<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.22<br/> (0.05 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 fewer per 1000<br/> (43 fewer to 1 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for study limitations: unclear risk of bias for one or more domains in the included study.<br/> <sup>2</sup>Downgraded by one level for imprecision: no event in either group.<br/> <sup>3</sup>Downgraded by one level for imprecision: confidence interval crossed assumed threshold of clinically important difference. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012059-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012059-sec-0023"></div> <section id="CD012059-sec-0024"> <h3 class="title" id="CD012059-sec-0024">Description of the condition</h3> <p>Nocturia is defined as waking at night one or more times to pass urine with each void being preceded and followed by sleep. This is distinct from nocturnal enuresis, which is defined as voiding during sleep (<a href="./references#CD012059-bbs2-0082" title="VanKerrebroeckP , AbramsP , ChaikinD , DonovanJ , FondaD , JacksonS , et al. The standardisation of terminology in nocturia: report from the Standardisation Subcommittee of the International Continence Society. Neurourology and Urodynamics2002;21(2):179‐83. ">Van Kerrebroeck 2002</a>). Although somewhat controversial, clinically significant nocturia is defined as one or more voids per night (<a href="./references#CD012059-bbs2-0038" title="AbramsP , CardozoL , FallM , GriffithsD , RosierP , UlmstenU , et al. Standardisation Sub‐committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub‐committee of the International Continence Society. Neurourology and Urodynamics2002;21(2):167‐78. ">Abrams 2002</a>). Nocturia is one of the most bothersome lower urinary tract symptoms (LUTS), with a correlation between degree of severity and increased bother (<a href="./references#CD012059-bbs2-0041" title="BliwiseDL , FoleyDJ , VitiellMV , AnsariFP , Ancoli‐IsraelS , WalshJK . Nocturia and disturbed sleep in the elderly. Sleep Medicine2009;10(5):540‐8. ">Bliwise 2009</a>). </p> <section id="CD012059-sec-0025"> <h4 class="title">Pathophysiology</h4> <p>Nocturia occurs when nocturnal urine volume exceeds the maximal voiding volume, which is reflective of the functional bladder capacity (<a href="./references#CD012059-bbs2-0042" title="BoschJL , WeissJP . The prevalence and causes of nocturia. Journal of Urology2013;189(1 Suppl):86‐92. ">Bosch 2013</a>; <a href="./references#CD012059-bbs2-0046" title="CornuJN , AbramsP , ChappleCR , DmochowskiRR , LemackGE , MichelMC , et al. A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management ‐ a systematic review and meta‐analysis. European Urology2012;62(5):877‐90. ">Cornu 2012</a>). The maximal voiding volume may be different at night than it is during the day. Nocturia has both urologic and non‐urologic causes that are behavioural, physiological, or pathologic in nature. Overall, the causes fall into four main categories: reduced bladder capacity secondary to anatomical or functional factors, which may or may not only occur at night; overall increase in urine production (24‐hour polyuria); nocturnal polyuria; or any primary or secondary sleep disorder (<a href="./references#CD012059-bbs2-0042" title="BoschJL , WeissJP . The prevalence and causes of nocturia. Journal of Urology2013;189(1 Suppl):86‐92. ">Bosch 2013</a>; <a href="./references#CD012059-bbs2-0046" title="CornuJN , AbramsP , ChappleCR , DmochowskiRR , LemackGE , MichelMC , et al. A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management ‐ a systematic review and meta‐analysis. European Urology2012;62(5):877‐90. ">Cornu 2012</a>). Benign prostatic hyperplasia (BPH) contributes to, but is not the sole cause of, LUTS, including nocturia. Benign prostatic hyperplasia can cause bladder outlet obstruction, which may induce secondary bladder overactivity and reduction in functional bladder capacity, resulting in nocturia (<a href="./references#CD012059-bbs2-0085" title="YoshimuraK , OharaH , IchiokaK , TeradaN , MatsuiY , TeraiA , et al. Nocturia and benign prostatic hyperplasia. Urology2003;61(4):786‐90. ">Yoshimura 2003</a>). Men may also experience nocturia with or without detrusor overactivity or postvoid residual urine (<a href="./references#CD012059-bbs2-0040" title="BergesR , HöfnerK , GedamkeM , OelkeM . Impact of desmopressin on nocturia due to nocturnal polyuria in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). World Journal of Urology2014;32(5):1163‐70. ">Berges 2014</a>). </p> </section> <section id="CD012059-sec-0026"> <h4 class="title">Epidemiology</h4> <p>Nocturia can affect any population at any age, however its incidence generally increases with age. Nocturia defined as one or more micturitions at night affects 20.4% to 43.9% of men aged 20 to 40 years and 68.9% to 93% in men older than 70 years (<a href="./references#CD012059-bbs2-0042" title="BoschJL , WeissJP . The prevalence and causes of nocturia. Journal of Urology2013;189(1 Suppl):86‐92. ">Bosch 2013</a>). </p> </section> <section id="CD012059-sec-0027"> <h4 class="title">Risk factors</h4> <p>Risk factors for nocturia are dependent upon the underlying causes, which can be overlapping. General risk factors include advancing age, higher body mass index, alcohol consumption, smoking, hypertension, cardiovascular disease, cerebrovascular disease, diabetes mellitus, and metabolic syndrome (<a href="./references#CD012059-bbs2-0085" title="YoshimuraK , OharaH , IchiokaK , TeradaN , MatsuiY , TeraiA , et al. Nocturia and benign prostatic hyperplasia. Urology2003;61(4):786‐90. ">Yoshimura 2003</a>). Men with LUTS suggestive of BPH are more susceptible to nocturia than are men without LUTS. Advancing age, smaller functional bladder capacity, increased nocturnal urine volume, and severity of urgency are predictors of frequent nocturnal voiding (<a href="./references#CD012059-bbs2-0085" title="YoshimuraK , OharaH , IchiokaK , TeradaN , MatsuiY , TeraiA , et al. Nocturia and benign prostatic hyperplasia. Urology2003;61(4):786‐90. ">Yoshimura 2003</a>). Overall, age is considered the most important risk factor (<a href="./references#CD012059-bbs2-0086" title="YoshimuraK . Correlates for nocturia: a review of epidemiological studies. International Journal of Urology2012;19(4):317‐29. ">Yoshimura 2012</a>). </p> </section> <section id="CD012059-sec-0028"> <h4 class="title">Diagnosis</h4> <p>Initial assessment of nocturia includes patient history, review of current medications, physical exam including a digital rectal examination in men, urinalysis, measurement of postvoid residual volumes, and validated symptom questionnaires such as the Nocturia‐Quality of Life questionnaire (N‐QoL) and the International Prostate Symptom Score (IPSS) (<a href="./references#CD012059-bbs2-0037" title="AbrahamL , HareendranA , MillsIW , MartinML , AbramsP , DrakeMJ , et al. Development and validation of a quality‐of‐life measure for men with nocturia. Urology2004;64(3):481‐6. ">Abraham 2004</a>). Other tests that may be necessary include uroflowmetry, urodynamic evaluation of bladder function, cystoscopy, bladder biopsies, sleep laboratory evaluation, and advanced cardiology tests (<a href="./references#CD012059-bbs2-0072" title="OelkeM , AdlerE , Marschall‐KehrelD , HerrmannTRW , BergesR . Nocturia: state of the art and critical analysis of current assessment and treatment strategies. World Journal of Urology2014;32(5):1109‐17. ">Oelke 2014a</a>). A potential dilemma in diagnosing nocturia in men is that it is often not the only symptom mentioned during medical consultations, and it is rarely the symptom that prompted seeking medical evaluation. Its evaluation is therefore often limited to patient‐reported numbers of voids per night as an item on the IPSS and subjective history. The International Continence Society encourages the use of the frequency volume chart, an important diagnostic tool that involves the person recording the time and volume of all voids as well as incontinence episodes and the number of incontinence pads used over a specific time, which is usually seven days (<a href="./references#CD012059-bbs2-0082" title="VanKerrebroeckP , AbramsP , ChaikinD , DonovanJ , FondaD , JacksonS , et al. The standardisation of terminology in nocturia: report from the Standardisation Subcommittee of the International Continence Society. Neurourology and Urodynamics2002;21(2):179‐83. ">Van Kerrebroeck 2002</a>). </p> </section> <section id="CD012059-sec-0029"> <h4 class="title">Treatment</h4> <p>Treatment is dependent upon the cause of nocturia as well as the person's individual treatment goals. Goals that are cited as being important include decreasing the number of nocturnal voiding episodes, prolongation of undisturbed sleep to greater than four hours, and improvement of sleep quality (<a href="./references#CD012059-bbs2-0072" title="OelkeM , AdlerE , Marschall‐KehrelD , HerrmannTRW , BergesR . Nocturia: state of the art and critical analysis of current assessment and treatment strategies. World Journal of Urology2014;32(5):1109‐17. ">Oelke 2014a</a>). Treatment for nocturia can be divided into behavioural modification, medical management, and surgical modalities. </p> <section id="CD012059-sec-0030"> <h5 class="title">Behavioural treatment</h5> <p>Although treatment should be centred on the cause of nocturia, behavioural modifications appear to be universally beneficial regardless of underlying aetiology. Lifestyle modification is therefore often used as first‐line therapy (<a href="./references#CD012059-bbs2-0083" title="VanKerrebroeckP , HashimH , Holm‐LarsenT , RobinsonD , StanleyN . Thinking beyond the bladder: antidiuretic treatment of nocturia. International Journal of Clinical Practice2010;64(6):807‐16. ">Van Kerrebroeck 2010</a>). Behavioural treatments include restriction of fluids before going to sleep, avoiding caffeinated or alcoholic beverages in the evening, pre‐emptive voiding immediately before going to bed, strategic medication timing, leg elevation in the case of lower extremity oedema, moderate physical exercise, and keeping warm in bed. Lifestyle modifications have been associated with up to 50% of people reporting improvement in nocturia (<a href="./references#CD012059-bbs2-0081" title="SodaT , MasuiK , OkunoH , TeraiA , OgawaO , YoshimuraK . Efficacy of nondrug lifestyle measures for the treatment of nocturia. Journal of Urology2010;184(3):1000‐4. ">Soda 2010</a>). </p> </section> <section id="CD012059-sec-0031"> <h5 class="title">Medical management</h5> <p>Medical management includes therapy with a single drug or a combination of drugs from different classes. Nocturia has historically been considered a symptom secondary to underlying bladder or prostate dysfunction, therefore therapies have been targeted towards these conditions. Current therapies include antimuscarinics, alpha‐1 adrenergic receptor blockers, 5‐alpha‐reductase inhibitors, phosphodiesterase type 5 inhibitors, anti‐inflammatory drugs, and desmopressin. </p> <p>The use of alpha‐1 adrenergic receptor blockers and 5‐alpha‐reductase inhibitors are in the context of BPH management, with only a few studies focusing on nocturia as a primary outcome. Overall, the evidence supporting the efficacy of alpha‐1 adrenergic receptor blockers and 5‐alpha‐reductase inhibitors in treating nocturia is low with inconsistent evidence that at best accounts for minor improvements (<a href="./references#CD012059-bbs2-0076" title="SchneiderT , de laRosetteJJMCH , MichelMC . Nocturia: a non‐specific but important symptom of urological disease. International Journal of Urology2009;16(3):249‐56. ">Schneider 2009</a>). In one large study analysing 3047 men randomised to one of four groups (doxazosin, finasteride, doxazosin plus finasteride, and placebo), the doxazosin and doxazosin plus finasteride groups showed statistically significant mean reductions in the number of nocturia episodes by 0.77 for doxazosin and 0.80 for doxazosin plus finasteride at one year (<a href="./references#CD012059-bbs2-0064" title="JohnsonTM , BurrowsPK , KusekeJW , NybergeLM , TenoverbJL , LeporfH , et al. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. Journal of Urology2007;178(5):2045‐51. ">Johnson 2007</a>). The placebo group had a decrease in the mean number of nocturia episodes by 0.61 and the finasteride group had a decrease of 0.60 at one year. These results were modest, and whether they are clinically significant is highly questionable. </p> <p>Tadalafil is a phosphodiesterase type 5 inhibitor that also has approval for treatment of LUTS/BPH. Integrated data from four randomised, placebo‐controlled studies investigating the use of daily tadalafil for nocturia found a mean decrease in the number of episodes of 0.4 in the placebo group and 0.5 in the tadalafil group (<a href="./references#CD012059-bbs2-0073" title="OelkeM , WeissJP , MamoulakisC , CoxD , RuffD , ViktrupL . Effects of tadalafil on nighttime voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a post hoc analysis of pooled data from four randomized, placebo‐controlled clinical studies. World Journal of Urology2014;32(5):1127‐32. ">Oelke 2014b</a>). While the difference between groups was statistically significant, the difference was very small and unlikely to be indicative of a clinically meaningful improvement. </p> <p>Most studies on antimuscarinics such as solifenacin and tolterodine are in the context of overactive bladder management, and evidence that they are effective for the specific management of nocturia is limited. The clinical impact of these agents is also questionable, as they result in a reduction of half a void or less per night (<a href="./references#CD012059-bbs2-0080" title="SmithAL , WeinAJ . Outcomes of pharmacological management of nocturia with non‐antidiuretic agents: does statistically significant equal clinically significant?. BJU International2011;107(10):1550‐4. ">Smith 2011</a>). The population that may benefit most from these agents are people with severe overactive bladder who have frequent nighttime awakenings associated with urgency. </p> <p>Few studies have been done on anti‐inflammatory drugs for nocturia. One study evaluating celecoxib in men with BPH with refractory nocturia showed promising results (<a href="./references#CD012059-bbs2-0050" title="FalahatkarS , MokhtariS , PourrezaF , AlaeddinAS , AlirezaNK . Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double‐blind, placebo‐controlled study. Urology2008;72(4):813‐6. ">Falahatkar 2008</a>). Men in the active treatment group had a statistically significant decrease in nocturnal frequency from (mean ± standard deviation (SD)) 5.17 ± 2.1 episodes to 2.5 ± 1.9 episodes, a dramatic response that is better than any other treatment modality. However, this study included only 80 men and was for a period of only four weeks. Without more reports with longer follow‐up and larger study populations, the evidence to support the use of anti‐inflammatory drugs for nocturia in men remains unclear. </p> </section> <section id="CD012059-sec-0032"> <h5 class="title">Surgical management</h5> <p>Surgical treatment may be appropriate for men with nocturia due to LUTS related to benign prostatic obstruction, although no surgical therapy is specifically indicated for nocturia (<a href="./references#CD012059-bbs2-0046" title="CornuJN , AbramsP , ChappleCR , DmochowskiRR , LemackGE , MichelMC , et al. A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management ‐ a systematic review and meta‐analysis. European Urology2012;62(5):877‐90. ">Cornu 2012</a>). Surgical options to reduce prostatic obstruction include transurethral resection of the prostate, transurethral incision of the prostate, transurethral microwave therapy of the prostate, and prostatectomy. Transurethral resection of the prostate has been associated with a one‐point reduction in nocturia, which correlates to one less nightly episode (<a href="./references#CD012059-bbs2-0084" title="WadaN , NumataA , HouK , WatanabeM , KitaM , MatsumotoS , et al. Nocturia and sleep quality after transurethral resection of the prostate. International Journal of Urology2014;21(1):82‐5. ">Wada 2014</a>; <a href="./references#CD012059-bbs2-0085" title="YoshimuraK , OharaH , IchiokaK , TeradaN , MatsuiY , TeraiA , et al. Nocturia and benign prostatic hyperplasia. Urology2003;61(4):786‐90. ">Yoshimura 2003</a>). Prostatectomy has been associated with a decrease in nighttime voiding frequency of 0.8 (mean ± SD): from 3.4 ± 1.2 episodes to 2.6 ± 0.99 episodes (<a href="./references#CD012059-bbs2-0069" title="MargelD , LifshitzD , BrownN , LaskD , LivnePM , TalR . Predictors of nocturia quality of life before and shortly after prostatectomy. Urology2007;70(3):493‐7. ">Margel 2007</a>). Other interventions such as botulinum toxin detrusor injection, sacral neuromodulation, or tibial electric nerve stimulation are used in the context of overactive bladder where nocturia is regarded a secondary outcome (<a href="./references#CD012059-bbs2-0046" title="CornuJN , AbramsP , ChappleCR , DmochowskiRR , LemackGE , MichelMC , et al. A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management ‐ a systematic review and meta‐analysis. European Urology2012;62(5):877‐90. ">Cornu 2012</a>). </p> </section> </section> </section> <section id="CD012059-sec-0033"> <h3 class="title" id="CD012059-sec-0033">Description of the intervention</h3> <p>Desmopressin is the synthetic analogue of the human hormone vasopressin, which has been used clinically in a variety of formulations since 1974. Vasopressin, also known as antidiuretic hormone, is produced by the posterior pituitary gland, and its role is to maintain serum osmolality and volume via modulation of free water excretion. Vasopressin is released in states of hyperosmolality and hypovolaemia, which is detected by chemoreceptors and baroreceptors located in the hypothalamus and carotid sinus, respectively. It acts on the V2 receptors in the distal collecting tubules, which subsequently results in translocation of aquaporin channels associated with cytosolic vesicles to the apical membrane of collecting duct cells. Free water is then passively reabsorbed from the nephron back into the systemic circulation via basolateral membrane channels. Vasopressin also plays a minor role in increasing systemic vascular resistance and increasing urea reabsorption in the medullary collecting tubule (<a href="./references#CD012059-bbs2-0079" title="ShoskesD , McMahonA . Renal physiology and pathophysiology. In: WeinA , KavoussiL , NovickA , ParitnA editor(s). Campbell‐Walsh Urology. 10th Edition. Philadelphia (PA): Saunders Elsevier, 2011. ">Shoskes 2011</a>). It is the most frequently tested medication for the specific treatment of nocturia, but has traditionally been used to treat central diabetes insipidus, bleeding disorders such as Von Willebrand disease, and primary nocturnal enuresis. The US Food and Drug Administration (FDA) approved desmopressin acetate nasal spray with the trademark name of NOCTIVA in March 2017 for nocturia due to nocturnal polyuria in adults who awaken at least twice per night to void (<a href="./references#CD012059-bbs2-0078" title="SerenityPharmaceuticals . US FDA approves Serenity Pharmaceutical's Noctiva (desmopressin acetate) ‐ the first drug approved for the treatment of nocturia. serenitypharma.com/noctiva/#sthash.V2dLtITW.dpbs (accessed 1 May 2017). ">Serenity Pharmaceuticals 2017</a>). </p> <section id="CD012059-sec-0034"> <h4 class="title">Adverse events of the intervention</h4> <p>The most frequently encountered adverse events include headache, hyponatraemia, insomnia, dry mouth, hypertension, abdominal pain, peripheral oedema, and nausea (<a href="./references#CD012059-bbs2-0053" title="FriedmanFM , WeissJP . Desmopressin in the treatment of nocturia: clinical evidence and experience. Therapeutic Advances in Urology2013;5(6):310‐7. ">Friedman 2013</a>). </p> </section> </section> <section id="CD012059-sec-0035"> <h3 class="title" id="CD012059-sec-0035">How the intervention might work</h3> <p>Desmopressin is effective in the treatment of polyuric states, and nocturnal polyuria is very common in people with nocturia (as high as 82.9%) (<a href="./references#CD012059-bbs2-0044" title="ChangSC , LinAT , ChenKK , ChangLS . Multifactorial nature of male nocturia. Urology2006;67(3):541‐4. ">Chang 2006</a>). Desmopressin may help alleviate nocturnal voiding by inducing antidiuresis resulting in increased urine osmolality and decreased urine output. </p> </section> <section id="CD012059-sec-0036"> <h3 class="title" id="CD012059-sec-0036">Why it is important to do this review</h3> <p>Nocturia may decrease quality of life and is associated with a high degree of bother. Reduced sleep due to nocturia has been associated with diurnal fatigue, decreased concentration, lower performance at work, and accidents from cognitive and motor impairment (<a href="./references#CD012059-bbs2-0039" title="AsplundR . Nocturia: consequences for sleep and daytime activities and associated risks. European Urology Supplements2005;3(6):24‐32. ">Asplund 2005</a>; <a href="./references#CD012059-bbs2-0045" title="Chartier‐KastlerE , ChappleCR . LUTS/BPH in clinical practice: the importance of nocturia and quality of sleep. BJU International2006;98(Suppl S2):3‐8. ">Chartier‐Kastler 2006</a>). In the elderly population, nocturia is associated with an increased risk of bone fractures due to nighttime falls (<a href="./references#CD012059-bbs2-0070" title="NakagawaH , NiuK , HozawaA , IkedaY , KaihoY , Ohmori‐MatsudaK , et al. Impact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort study. Journal of Urology2010;184(4):1413‐8. ">Nakagawa 2010</a>). Although various treatment modalities have been used to treat LUTS successfully, nocturia remains one of the most elusive and problematic symptoms. </p> <p>There are also inherent risks in recommending a medication to treat a symptom if the underlying disease process is not thoughtfully considered. Desmopressin can also cause hyponatraemia, which is often asymptomatic but in limited cases can have deleterious effects. With regard to assessing efficacy, a common outcome measure is the decrease in the number of nocturnal voids, however there is no existing consensus on its clinical significance. To better assess clinically meaningful efficacy it is therefore crucial to critically analyse and synthesise the symptoms, quality of life measures, and sleep parameters in existing clinical trials (<a href="./references#CD012059-bbs2-0046" title="CornuJN , AbramsP , ChappleCR , DmochowskiRR , LemackGE , MichelMC , et al. A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management ‐ a systematic review and meta‐analysis. European Urology2012;62(5):877‐90. ">Cornu 2012</a>). </p> <p>One systematic review on this topic exists (<a href="./references#CD012059-bbs2-0048" title="EbellMH , RadkeT , GardnerJ . A systematic review of the efficacy and safety of desmopressin for nocturia in adults. Journal of Urology2014;192(3):829‐35. ">Ebell 2014</a>). However, no review has used GRADE to assess the quality of evidence supporting the use of desmopressin for the treatment of nocturia in men. Given the modest efficacy and questionable clinical significance of the multiple medical and surgical treatments for nocturia in men, such an investigation into the effects of desmopressin based on the totality of available evidence as summarised in a rigorous systematic review is critically important. In an era of rising health costs and an increased emphasis on evidence‐based medicine, the findings of this review will be especially relevant to policymakers and healthcare providers. Furthermore, as a drug can gain regulatory approval based on statistical significance, it is important to know that this does not automatically mean that the drug has a clinically significant impact. This is of particular concern when the effect size is small or when the potential adverse events are considerable, or both (<a href="./references#CD012059-bbs2-0051" title="FralickM , KesselheimAS . FDA approval of desmopressin for nocturia. JAMA2017;317(20):2059‐60. ">Fralick 2017</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012059-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012059-sec-0037"></div> <p>To assess the effects of desmopressin as compared to other interventions in the treatment of nocturia in men. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012059-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012059-sec-0038"></div> <section id="CD012059-sec-0039"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012059-sec-0040"> <h4 class="title">Types of studies</h4> <p>We included randomised or quasi‐randomised trials regardless of their publication status or language of publication. </p> </section> <section id="CD012059-sec-0041"> <h4 class="title">Types of participants</h4> <p>Men with nocturia defined as one or more voids per night (<a href="./references#CD012059-bbs2-0038" title="AbramsP , CardozoL , FallM , GriffithsD , RosierP , UlmstenU , et al. Standardisation Sub‐committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub‐committee of the International Continence Society. Neurourology and Urodynamics2002;21(2):167‐78. ">Abrams 2002</a>). We excluded trials of children or adults with primary or secondary enuresis or underlying distinct disorders such as Cushing disease, multiple sclerosis, or autonomic dysfunction. </p> <p>We mostly included studies focused on this specific population of participants. In addition, we included studies in which a subset of participants met our inclusion criteria, if relevant data were reported separately to permit data analysis. </p> </section> <section id="CD012059-sec-0042"> <h4 class="title">Types of interventions</h4> <p>We planned to investigate the following comparisons of experimental intervention versus comparator intervention. </p> <section id="CD012059-sec-0043"> <h5 class="title">Experimental interventions</h5> <p> <ul id="CD012059-list-0001"> <li> <p>Desmopressin.</p> </li> <li> <p>Desmopressin plus other drug treatment for LUTS.</p> </li> </ul> </p> </section> <section id="CD012059-sec-0044"> <h5 class="title">Comparator interventions</h5> <p> <ul id="CD012059-list-0002"> <li> <p>Placebo.</p> </li> <li> <p>Behavioural modifications.</p> </li> <li> <p>Drug treatments for LUTS.</p> </li> <li> <p>Surgery for LUTS.</p> </li> </ul> </p> </section> <section id="CD012059-sec-0045"> <h5 class="title">Comparisons</h5> <p> <ul id="CD012059-list-0003"> <li> <p>Desmopressin versus placebo.</p> </li> <li> <p>Desmopressin versus behavioural modification.</p> </li> <li> <p>Desmopressin versus drug treatment for LUTS.</p> </li> <li> <p>Desmopressin plus other drug treatment for LUTS versus drug treatment for LUTS alone.</p> </li> <li> <p>Desmopressin versus surgery for LUTS.</p> </li> </ul> </p> <p>We required that concomitant interventions be the same in the experimental and comparator groups to establish fair comparisons. </p> </section> </section> <section id="CD012059-sec-0046"> <h4 class="title">Types of outcome measures</h4> <p>We did not use the measurement of the outcomes specified in this review as an eligibility criterion. </p> <section id="CD012059-sec-0047"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012059-list-0004"> <li> <p>Number of nocturnal voids.</p> </li> <li> <p>Quality of life.</p> </li> <li> <p>Major adverse events.</p> </li> </ul> </p> </section> <section id="CD012059-sec-0048"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012059-list-0005"> <li> <p>Duration of first sleep episode.</p> </li> <li> <p>Time to first void.</p> </li> <li> <p>Minor adverse events.</p> </li> <li> <p>Treatment withdrawal due to adverse event.</p> </li> </ul> </p> <section id="CD012059-sec-0049"> <h6 class="title">Method and timing of outcome measurement</h6> <p>We used clinically important differences (CID) for each outcome to rate the quality of the evidence in the 'Summary of findings' tables (<a href="./references#CD012059-bbs2-0065" title="JohnstonBC , ThorlundK , SchunemannHJ , XieF , MuradMH , MontoriVM , et al. Improving the interpretation of quality of life evidence in meta‐analyses: the application of minimal important difference units. Health and Quality of Life Outcomes2010;8:116. ">Johnston 2010</a>). </p> <section id="CD012059-sec-0050"> <p><b>Number of nocturnal voids</b></p> <p> <ul id="CD012059-list-0006"> <li> <p>Measured by voiding diary (final value or change from baseline).</p> </li> <li> <p>Minimal clinically important differences (MCIDs) for outcomes when treating nocturia have not been defined. We considered improvement of nocturia of at least one episode per night as CID for nocturia (<a href="./references#CD012059-bbs2-0067" title="KraderCG . Antimuscarinic decreases nocturnal urgency episodes. urologytimes.modernmedicine.com/urology‐times/news/clinical/clinical‐pharmacology/antimuscarinic‐decreases‐nocturnal‐urgency‐episode (accessed 5 September 2017). ">Krader 2012</a>). </p> </li> </ul> </p> </section> <section id="CD012059-sec-0051"> <p><b>Quality of life</b></p> <p> <ul id="CD012059-list-0007"> <li> <p>Assessed using condition‐specific, validated health measures (such as IPSS and N‐QoL; final value or change from baseline). </p> </li> <li> <p>We used an MCID of one point for IPSS‐QoL to assess efficacy and comparative effectiveness (<a href="./references#CD012059-bbs2-0043" title="BrasureM , MacDonaldR , DahmP , OlsonCM , NelsonVA , FinkHA , et al. Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Review. Comparative Effectiveness Review No 178... Rockville (MD): Agency for Healthcare Research and Quality, May 2016. ">Brasure 2016</a>). While no thresholds were established for N‐QoL and Impact of Nighttime Urination, we used a CID of eight points for both questionnaires to assess efficacy and comparative effectiveness (<a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>). </p> </li> </ul> </p> </section> <section id="CD012059-sec-0052"> <p><b>Major adverse events</b></p> <p> <ul id="CD012059-list-0008"> <li> <p>Such as symptomatic hyponatraemia, arrhythmia, need for hospital admission, respiratory insufficiency. </p> </li> </ul> </p> </section> <section id="CD012059-sec-0053"> <p><b>Duration of first sleep episode</b></p> <p> <ul id="CD012059-list-0009"> <li> <p>Measured by voiding diary (final value or change from baseline).</p> </li> </ul> </p> </section> <section id="CD012059-sec-0054"> <p><b>Time to first void</b></p> <p> <ul id="CD012059-list-0010"> <li> <p>Measured by voiding diary (final value or change from baseline).</p> </li> </ul> </p> </section> <section id="CD012059-sec-0055"> <p><b>Minor adverse events</b></p> <p> <ul id="CD012059-list-0011"> <li> <p>Such as asymptomatic hyponatraemia requiring treatment, headache, nausea, insomnia, dry mouth, hypertension, abdominal pain, and peripheral oedema. </p> </li> </ul> </p> </section> <section id="CD012059-sec-0056"> <p><b>Treatment withdrawal due to adverse event</b></p> <p> <ul id="CD012059-list-0012"> <li> <p>Defined as treatment discontinuation from any cause at any time after men were randomised to intervention/comparator groups. </p> </li> </ul> </p> <p>The CID for the duration of first sleep episode, time to first void, major and minor adverse events, and treatment withdrawal due to adverse event have not been defined. We considered improvement of at least one hour per night as the CID for duration of first sleep episode and time to first void. We considered the CID for major and minor adverse events, and treatment withdrawal due to adverse event as a relative risk reduction of at least 25% (<a href="./references#CD012059-bbs2-0056" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence ‐ imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. ">Guyatt 2011a</a>). </p> <p>We separately considered outcomes measured up to three months (short term), more than three months up to 12 months (intermediate term), and more than 12 months (long term). </p> </section> </section> <section id="CD012059-sec-0057"> <h6 class="title">Main outcomes for 'Summary of findings' tables</h6> <p>We presented 'Summary of findings' tables for the following outcomes.</p> <p> <ul id="CD012059-list-0013"> <li> <p>Number of nocturnal voids.</p> </li> <li> <p>Quality of life.</p> </li> <li> <p>Major adverse events.</p> </li> <li> <p>Duration of first sleep episode.</p> </li> <li> <p>Time to first void.</p> </li> <li> <p>Minor adverse events.</p> </li> <li> <p>Treatment withdrawal due to adverse event.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD012059-sec-0058"> <h3 class="title">Search methods for identification of studies</h3> <p>We performed a comprehensive search with no restrictions on the language of publication or publication status. </p> <section id="CD012059-sec-0059"> <h4 class="title">Electronic searches</h4> <p>We searched the following sources from inception of each database. We initially searched the following sources from inception to 22 June 2015. The date of last search of all databases was 1 August 2017. </p> <p> <ul id="CD012059-list-0014"> <li> <p>The Cochrane Library (from 1991 via Wiley for the search strategy, see <a href="./appendices#CD012059-sec-0207">Appendix 2</a>); </p> <ul id="CD012059-list-0015"> <li> <p>Cochrane Database of Systematic Reviews (CDSR);</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>Database of Abstracts of Reviews of Effects (DARE);</p> </li> <li> <p>Health Technology Assessment (HTA) Database.</p> </li> </ul> </li> </ul> <ul id="CD012059-list-0016"> <li> <p>MEDLINE (from 1946 via Ovid; <a href="./appendices#CD012059-sec-0208">Appendix 3</a>). </p> </li> <li> <p>EMBASE (from 1974 via Ovid; <a href="./appendices#CD012059-sec-0209">Appendix 4</a>). </p> </li> <li> <p>Scopus (from 1966; <a href="./appendices#CD012059-sec-0210">Appendix 5</a>). </p> </li> <li> <p>Google Scholar (<a href="./appendices#CD012059-sec-0211">Appendix 6</a>). </p> </li> <li> <p>Web of Science (from 1900; <a href="./appendices#CD012059-sec-0212">Appendix 7</a>). </p> </li> <li> <p>Western Pacific Region Index Medicus (from 1950; <a href="./appendices#CD012059-sec-0213">Appendix 8</a>). </p> </li> </ul> </p> <p>We also searched the following clinical trial registries. The date of last search of all clinical trial registries was 1 August 2017. </p> <p> <ul id="CD012059-list-0017"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov/</a>; <a href="./appendices#CD012059-sec-0214">Appendix 9</a>). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>; <a href="./appendices#CD012059-sec-0215">Appendix 10</a>). </p> </li> </ul> </p> </section> <section id="CD012059-sec-0060"> <h4 class="title">Searching other resources</h4> <p>We attempted to identify other potentially eligible trials or ancillary publications by searching the reference lists of retrieved included trials, reviews, meta‐analyses, and health technology assessment reports. We also contacted study authors of included trials to identify any further studies that we may have missed. </p> <p>We contacted Ferring Pharmaceuticals, the sponsor of several trials, for ongoing or unpublished trials. We also searched for unpublished studies by handsearching the abstract proceedings of the annual meetings of the American Urological Association, European Association of Urology, International Continence Society, and the British Association of Urological Surgeons from 2012 to 2017. </p> </section> </section> <section id="CD012059-sec-0061"> <h3 class="title" id="CD012059-sec-0061">Data collection and analysis</h3> <section id="CD012059-sec-0062"> <h4 class="title">Selection of studies</h4> <p>We used reference management software to identify and remove potential duplicate records (<a href="./references#CD012059-bbs2-0049" title="Clarivate Analytics. EndNote. Version 7.5. Clarivate Analytics, 2016. ">EndNote</a>). Two review authors (JH, JHJ) independently scanned the abstract, title, or both, of the remaining records to determine which studies should be assessed further in <a href="./references#CD012059-bbs2-0047" title="Melbourne, Australia: Veritas Health Innovation. Covidence systematic review software. www.covidence.org. Melbourne, Australia: Veritas Health Innovation, 2013. ">Covidence</a>. In the second stage, two review authors (JH, JHJ) investigated all potentially relevant records as full text; mapped records to studies; and classified studies as included studies, excluded studies, studies awaiting classification, or ongoing studies in accordance with the criteria for each provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012059-bbs2-0061" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). Any discrepancies were resolved through consensus or recourse to a third review author (PD). We documented reasons for exclusion of studies that may have reasonably been expected to have been included in the review in the <a href="./references#CD012059-sec-0232" title="">Characteristics of excluded studies</a> table. We presented an adapted PRISMA flow diagram showing the process of study selection (<a href="./references#CD012059-bbs2-0068" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJPA , et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6(7):e1000100. [DOI: 10.1371/journal.pmed.1000100] ">Liberati 2009</a>). </p> </section> <section id="CD012059-sec-0063"> <h4 class="title">Data extraction and management</h4> <p>We developed a dedicated data abstraction form that we pilot tested ahead of time.</p> <p>Two review authors (JH, JHJ) independently abstracted the following information for studies that fulfilled our inclusion criteria, which we summarised in the <a href="./references#CD012059-sec-0231" title="">Characteristics of included studies</a> table. </p> <p> <ul id="CD012059-list-0018"> <li> <p>Study design.</p> </li> <li> <p>Study dates (if dates were not available, we reported this as such).</p> </li> <li> <p>Study settings and country.</p> </li> <li> <p>Participant inclusion and exclusion criteria.</p> </li> <li> <p>Participant details, baseline demographics.</p> </li> <li> <p>Number of participants by study and study arm.</p> </li> <li> <p>Details of relevant experimental and comparator interventions such as desmopressin dose, route, frequency, and duration. </p> </li> <li> <p>Definitions of relevant outcomes, and method and timing of outcome measurement as well as any relevant subgroups. </p> </li> <li> <p>Study funding sources.</p> </li> <li> <p>Declarations of interest by primary investigators.</p> </li> </ul> </p> <p>We extracted outcomes data relevant to this review as needed for the calculation of summary statistics and measures of variance. For dichotomous outcomes, we attempted to obtain numbers of events and totals for completion of a two‐by‐two table, as well as summary statistics with corresponding measures of variance. For continuous outcomes, we attempted to obtain means and SDs or data needed to calculate this information. </p> <p>Any disagreements were resolved by discussion or by consulting a third review author (PD). </p> <p>We attempted to contact authors of included studies to obtain key missing data as needed and documented these communications. </p> <section id="CD012059-sec-0064"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>In the event of duplicate publications, companion documents, or multiple reports of a primary study, we maximised the yield of information by mapping all publications to unique studies and collating all available data using the most complete data set aggregated across all known publications. </p> </section> </section> <section id="CD012059-sec-0065"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (JHJ, PD) independently assessed the risk of bias of each included study on a per‐outcome basis. We resolved all disagreements by discussion and consensus. </p> <p>We assessed risk of bias using the Cochrane 'Risk of bias' assessment tool employing the following domains (<a href="./references#CD012059-bbs2-0062" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). </p> <p> <ul id="CD012059-list-0019"> <li> <p>Random sequence generation (selection bias).</p> </li> <li> <p>Allocation concealment (selection bias).</p> </li> <li> <p>Blinding of participants and personnel (performance bias).</p> </li> <li> <p>Blinding of outcome assessment (detection bias).</p> </li> <li> <p>Incomplete outcome data (attrition bias).</p> </li> <li> <p>Selective reporting (reporting bias).</p> </li> <li> <p>Other sources of bias.</p> </li> </ul> </p> <p>We judged 'Risk of bias' domains as 'low risk', 'high risk', or 'unclear risk' and evaluated individual bias items as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012059-bbs2-0062" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). We presented a 'Risk of bias' summary figure to illustrate these findings. </p> <p>For selection bias (random sequence generation and allocation concealment) and reporting bias (selective reporting), we evaluated risk of bias at the level of the trial. </p> <p>For performance bias (blinding of participants and personnel) and detection bias (blinding of outcome assessment), we evaluated the risk of bias separately for each outcome. We considered all outcomes similarly susceptible to bias and assessed them as one group. </p> <p>We assessed attrition bias (incomplete outcome data) on an outcome‐specific basis. Since judgements were identical across some outcomes, we collapsed these ratings into groups when reporting our findings in the 'Risk of bias' tables. </p> <p>We further summarised the risk of bias across domains for each outcome in each included study, as well as across studies and domains for each outcome, in accordance with the approach for summary assessments of the risk of bias presented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012059-bbs2-0062" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). </p> </section> <section id="CD012059-sec-0066"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed dichotomous data as risk ratios (RR) with 95% confidence intervals (CIs). We expressed continuous data as mean differences (MD) with 95% CIs. </p> </section> <section id="CD012059-sec-0067"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant. We identified no cluster‐randomised trials. For cross‐over trials, we only considered data up to the time point that cross‐over occurred in accordance with guidance provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012059-bbs2-0063" title="HigginsJPT , DeeksJJ , AltmanDG . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011c</a>). </p> </section> <section id="CD012059-sec-0068"> <h4 class="title">Dealing with missing data</h4> <p>We sought to obtain missing data from study authors and to perform intention‐to‐treat analyses if data were available; we otherwise performed available‐case analyses, which we identified as such. We investigated attrition rates, for example dropouts, losses to follow‐up, and withdrawals, and critically appraised issues of missing data. We did not impute missing data. </p> </section> <section id="CD012059-sec-0069"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the event of excessive heterogeneity unexplained by subgroup analyses, we planned not to report outcome results as the pooled effect estimate in a meta‐analysis but to provide a narrative description of the results of each study only. </p> <p>We identified heterogeneity (inconsistency) through visual inspection of the forest plots to assess the amount of overlap of CIs, and the I<sup>2</sup> statistic, which quantifies inconsistency across studies to assess the impact of heterogeneity on the meta‐analysis (<a href="./references#CD012059-bbs2-0059" title="HigginsJPT , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. [DOI: 10.1002/sim.1186] ">Higgins 2002</a>; <a href="./references#CD012059-bbs2-0060" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ (Clinical Research Ed.)2003;327(7414):557‐60. [DOI: 10.1136/bmj.327.7414.557] ">Higgins 2003</a>). We interpreted the I<sup>2</sup> statistic as follows. </p> <p> <ul id="CD012059-list-0020"> <li> <p>0% to 40%: may not be important.</p> </li> <li> <p>30% to 60%: may indicate moderate heterogeneity.</p> </li> <li> <p>50% to 90%: may indicate substantial heterogeneity.</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>In the setting of heterogeneity, we planned to determine the possible reasons for the heterogeneity by examining individual study and subgroup characteristics. However, due to a paucity of studies for each comparison, this was not feasible. </p> </section> <section id="CD012059-sec-0070"> <h4 class="title">Assessment of reporting biases</h4> <p>We attempted to obtain study protocols to assess selective outcome reporting.</p> <p>For 10 or more studies investigating a particular outcome, we planned to use funnel plots to assess small‐study effects. However, the number of included studies was consistently too low to permit this type of analysis. </p> </section> <section id="CD012059-sec-0071"> <h4 class="title">Data synthesis</h4> <p>We summarised data using a random‐effects model. We interpreted random‐effects meta‐analyses with due consideration of the whole distribution of effects. In addition, we performed statistical analyses according to the statistical guidelines contained in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012059-bbs2-0061" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). We used the Mantel‐Haenszel method for dichotomous outcomes, and the inverse variance method for continuous outcomes. We performed all analyses in Review Manager 5 software (<a href="./references#CD012059-bbs2-0074" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> <section id="CD012059-sec-0072"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected the following characteristics to introduce clinical heterogeneity, and planned to carry out subgroup analyses with investigation of interactions limited to the primary outcomes. </p> <p> <ul id="CD012059-list-0021"> <li> <p>Routes of administration of desmopressin (intranasal versus sublingual versus oral) to evaluate whether the treatment effects depended on the routes of administration. The differences in the systemic absorption of the three administration routes are reflected in the bioavailability (<a href="./references#CD012059-bbs2-0052" title="FransénN , BredenbergS , BjörkE . Clinical study shows improved absorption of desmopressin with novel formulation. Pharmaceutical Research2009;26(7):1618‐25. ">Fransén 2009</a>). </p> </li> <li> <p>Desmopressin dose (less than 10 μg versus 10 μg or greater to less than 100 μg versus 100 μg or greater) to evaluate whether the efficacy of desmopressin depends on the dose. Statistically significant benefits have been seen with doses as low as 25 μg, however a greater magnitude of benefit has been shown with doses of 100 μg or higher with no associated statistically significant increase in adverse events (<a href="./references#CD012059-bbs2-0048" title="EbellMH , RadkeT , GardnerJ . A systematic review of the efficacy and safety of desmopressin for nocturia in adults. Journal of Urology2014;192(3):829‐35. ">Ebell 2014</a>). </p> </li> <li> <p>In men with or without nocturnal polyuria to evaluate whether desmopressin has more benefit in men with nocturnal polyuria (<a href="./references#CD012059-bbs2-0040" title="BergesR , HöfnerK , GedamkeM , OelkeM . Impact of desmopressin on nocturia due to nocturnal polyuria in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). World Journal of Urology2014;32(5):1163‐70. ">Berges 2014</a>). </p> </li> </ul> </p> <p>We used the test for subgroup differences in Review Manager 5 to compare subgroup analyses if there were sufficient studies (<a href="./references#CD012059-bbs2-0074" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> <section id="CD012059-sec-0073"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses to explore the influence of the following factors (when applicable) on effect sizes limited to the primary outcomes. </p> <p> <ul id="CD012059-list-0022"> <li> <p>Restricting the analysis by considering risk of bias, excluding studies at 'high risk' or 'unclear risk'. </p> </li> <li> <p>Restricting the analysis by considering risk of bias, excluding studies with run‐in periods. </p> </li> <li> <p>Restricting the analysis by considering the clinically recommended dosage of desmopressin, excluding lower dose levels. </p> </li> </ul> </p> <section id="CD012059-sec-0074"> <h5 class="title">'Summary of findings' tables</h5> <p>We presented the overall quality of the evidence for each outcome according to the GRADE approach, which considers five criteria not only related to internal validity (risk of bias, inconsistency, imprecision, publication bias) but also to external validity, such as directness of results (<a href="./references#CD012059-bbs2-0055" title='GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , SchünemannHJ , et al. GRADE: what is "quality of evidence" and why is it important to clinicians?. BMJ (Clinical Research Ed.)2008;336(7651):995‐8. [DOI: 10.1136/bmj.39490.551019.BE] '>Guyatt 2008</a>)<i>.</i> For each comparison, two review authors (JH, JHJ) independently rated the quality of evidence for each outcome as 'high', 'moderate', 'low', or 'very low' using GRADEpro GDT (<a href="./references#CD012059-bbs2-0054" title="McMaster University (developed by Evidence Prime, Inc.). GRADEpro GDT: GRADEpro Guideline Development Tool. Hamilton (ON): McMaster University (developed by Evidence Prime, Inc.), 2015. ">GRADEpro GDT</a>), resolving any discrepancies by consensus, or, if needed, by recourse to a third review author (PD). For each comparison, we presented a summary of the evidence for the main outcomes in 'Summary of findings' tables, which provided key information about the best estimate of the magnitude of the effect, in relative terms and absolute differences, for each relevant comparison of alternative management strategies; numbers of participants and studies addressing each important outcome; and the rating of the overall confidence in effect estimates for each outcome (<a href="./references#CD012059-bbs2-0057" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction ‐ GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. [DOI: 10.1016/j.jclinepi.2010.04.026] ">Guyatt 2011b</a>; <a href="./references#CD012059-bbs2-0077" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012059-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012059-sec-0075"></div> <section id="CD012059-sec-0076"> <h3 class="title">Description of studies</h3> <section id="CD012059-sec-0077"> <h4 class="title">Results of the search</h4> <p>Our comprehensive literature search identified 1524 records that included six records found through the trial registries and the New Drug Applications submitted to the FDA. After removal of duplicates, we screened the titles and abstracts of 1355 records and excluded 1298. We screened 57 full‐text articles and excluded 22 studies (23 articles). Seventeen studies did not meet the inclusion criteria or were not relevant to our review question (<a href="./references#CD012059-bbs2-0015" title="AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015b</a>; <a href="./references#CD012059-bbs2-0016" title="AsplundR , SundbergB , BengtssonP . Oral desmopressin for nocturnal polyuria in elderly subjects: a double‐blind, placebo‐controlled randomized exploratory study. BJU International1999;83(6):591‐5. [PUBMED: 10233563 ] ">Asplund 1999</a>; <a href="./references#CD012059-bbs2-0017" title="ChoSY , ParkJ , PiaoS , LeeSB , ChunJY , JeongH , et al. The effect of combined systematized behavioral modification education program (SBMP) with DDAVP in patients with nocturia: a multicenter, randomized, and parallel study. European Urology Supplements2015;14(2):e689‐e689b. [DOI: 10.1016/S1569‐9056(15)60681‐9] ">Cho 2015</a>; <a href="./references#CD012059-bbs2-0018" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] '>Cho 2016</a>; <a href="./references#CD012059-bbs2-0019" title="FuF , LaveryHJ , WuDL . Reducing nocturia in the elderly: a randomized placebo‐controlled trial of staggered furosemide and desmopressin. Neurourology and Urodynamics2011;30(3):312‐6. [PUBMED: 21305590 ] ">Fu 2011</a>; <a href="./references#CD012059-bbs2-0020" title="GilbertE , WahlquistAH . Oral desmopressin effective for nocturnal polyuria in men with benign prostatic hyperplasia. Journal of the National Medical Association2011;103(5):461. [DOI: 10.1016/S0027‐9684(15)30347‐3] ">Gilbert 2011</a>; <a href="./references#CD012059-bbs2-0021" title="Holm‐LarsenT , DijkD , BlemingsA , JuulKV . Kaplan‐Meier survival analysis indicates improved undisturbed initial sleep in nocturia patients treated with desmopressin. Sleep2013;36:A296. ">Holm‐Larsen 2013a</a>; <a href="./references#CD012059-bbs2-0022" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] ">Kaminetsky 2016</a>; <a href="./references#CD012059-bbs2-0023" title="LamYC , ChanCK , CheungFK . Efficacy and safety of minirin melt in elderly with nocturia ‐ a randomized double‐blinded placebo controlled trial. International Journal of Urology2017;24(Suppl 1):23. [DOI: 10.1111/iju.13413] ">Lam 2017</a>; <a href="./references#CD012059-bbs2-0024" title="MalliD , MorkunaiteD , GobleS , AndersonP , Holm‐LarsenT . QOL in patients with nocturia: does the study design impact the outcome?. Neurourology and Urodynamics2014;33(6):784‐6. [DOI: 10.1002/nau.22655] ">Malli 2014</a>; <a href="./references#CD012059-bbs2-0025" title="MoonDG , KoYH , JinMH , KimJJ . Effects of desmopressin on nocturia in adult. Journal of Urology2002;167(Suppl 4):267. ">Moon 2002</a>; <a href="./references#CD012059-bbs2-0026" title="MoonDG , KongSH , CheonJ , LeeJG , KimJJ . Antidiuretic hormone in adult nocturia. Journal of Urology2003;169(Suppl 4):334. [DOI: 10.1016/S0022‐5347(03)80069‐1] ">Moon 2003</a>; <a href="./references#CD012059-bbs2-0027" title="ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [DOI: 10.2147/CIA.S64194] ">Shin 2014b</a>; <a href="./references#CD012059-bbs2-0028" title="vanKerrebroeckP , RezapourM , CortesseA , ThuroffJ , RiisA , NorgaardJP . Desmopressin in the treatment of nocturia: a double‐blind, placebo‐controlled study. European Urology2007;52(1):221‐9. [DOI: 10.1016/j.eururo.2007.01.027] ">van Kerrebroeck 2007</a>; <a href="./references#CD012059-bbs2-0029" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011b</a>; <a href="./references#CD012059-bbs2-0030" title="WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21:S285‐7. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] ">Weiss 2012b</a>; <a href="./references#CD012059-bbs2-0031" title="YassinA , SaadF , HaiderA . Oral desmopressin in the treatment of nocturia in an aging population. Urology2010;3 Suppl:S40‐1. [DOI: 10.1016/j.urology.2010.07.435] ">Yassin 2010</a>). We identified four studies awaiting classification (<a href="./references#CD012059-bbs2-0032" title="Holm‐LarsenT , AnderssonF , YankovV , NorgaardJP . One month after treatment initiation nocturia patients slept significantly longer and better on treatment than placebo patients. Value in Health2013;16(3):A183. ">Holm‐Larsen 2013b</a>; <a href="./references#CD012059-bbs2-0033" title="NCT01694498 . A randomised, double‐blind, placebo‐controlled, parallel‐group, multi‐centre trial investigating the efficacy and safety of two different dose levels of desmopressin for the treatment of nocturia in adult men. clinicaltrials.gov/ct2/show/NCT01694498 (date first received 30 August 2017). ">NCT01694498</a>; <a href="./references#CD012059-bbs2-0034" title="SalvatoreS , HillS , CardozoL , KhullarV , AndersK , GleesonC . A double‐blind, placebo‐controlled trial of oral desmopressin in patients with nocturia. 26th Annual Meeting of the International Continence Society; 1996 Aug 27‐30; Athens, Greece1996. ">Salvatore 1996</a>; <a href="./references#CD012059-bbs2-0035" title="WeissJ , BlaivasJG , AbramsP , MattiassonA , RobertsonG , vanKerrebroeckP , et al. Oral desmopressin (Minirin, DDAVP) in the treatment of nocturia in men. Journal of Urology2001;165(5 Suppl):250. ">Weiss 2001</a>), and one ongoing trial (<a href="./references#CD012059-bbs2-0036" title="NCT02904759 . Trial of desmopressin orally disintegrating tablets (ODT) for nocturia due to nocturnal polyuria in Japanese male subjects. clinicaltrials.gov/ct2/show/NCT02904759 (date first received 30 August 2017). ">NCT02904759</a>). Fourteen studies (34 articles) ultimately met the inclusion criteria and were included in the qualitative synthesis of this review (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0002" title="CannonA , CarterPG , McConnellAA , AbramsP . Desmopressin in the treatment of nocturnal polyuria in the male. BJU International1999;84(1):20‐4. [PUBMED: 10444118 ] ">Cannon 1999</a>; <a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a>; <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>; <a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] ">Rezakhaniha 2011</a>; <a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a>; <a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>; <a href="./references#CD012059-bbs2-0011" title="WangW , ChenS . Low dose oral desmopressin in treatment of nocturia in elderly men. Urology2012;80(3 Suppl):S117. [DOI: 10.1016/S0090‐4295(12)00880‐1] ">Wang 2012</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). The flow of literature through this assessment process is shown in the PRISMA flowchart (<a href="#CD012059-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD012059-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram." data-id="CD012059-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram.</p> </div> </div> </div> </section> <section id="CD012059-sec-0078"> <h4 class="title">Included studies</h4> <p>A detailed description of the characteristics of included studies is presented elsewhere (see <a href="./references#CD012059-sec-0231" title="">Characteristics of included studies</a> table; <a href="#CD012059-tbl-0007">Table 1</a>; <a href="#CD012059-tbl-0008">Table 2</a>). </p> <div class="table" id="CD012059-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial period</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Description of participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of intervention<br/> (duration of follow‐up)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient/Egypt</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2011 to 2014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>People with LUTS/BPH aged ≥ 50 years with nocturia (≥ 2 voids/night), nocturnal polyuria (nocturnal urine volume &gt; 30% of 24‐hour urine volume) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin 60 μg ODT + tamsulosin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: tamsulosin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0002" title="CannonA , CarterPG , McConnellAA , AbramsP . Desmopressin in the treatment of nocturnal polyuria in the male. BJU International1999;84(1):20‐4. [PUBMED: 10444118 ] ">Cannon 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged &gt; 50 years with nocturnal polyuria (using 48‐hour inpatient monitoring or 1‐week frequency volume chart) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin nasal spray 20 μg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient/Turkey</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with advanced age, complaints of LUTS and nocturia (≥ 3 times/night)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin nasal spray 20 μg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: doxazosin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre/South Korea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged 40 to 65 years with LUTS (IPSS &gt; 13), nocturia (≥ 2 episodes/night), and nocturnal polyuria (NPI &gt; 33%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin 0.2 mg oral + alpha‐blocker</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + alpha‐blocker</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient/Turkey</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged 50 to 70 years with LUTS and nocturia (≥ 2/night)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin 0.2 mg oral with alfuzosin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: alfuzosin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre/Denmark,<br/> Sweden, Netherlands, the UK, and the USA </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged ≥ 18 years with nocturia (2 voids/night, nocturia index scores &gt; 1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin 0.1 mg/0.2 mg/0.4 mg oral; dose titration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] ">Rezakhaniha 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient/single centre/Iran</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2008 to 2009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Older men (mean age about 63 to 64 years) with voiding ≥ 2/night</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin 0.1 mg oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals</a><a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre/USA and Canada</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men or women aged ≥ 50 years with nocturia (≥ 2 nocturic episodes/night)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin nasal spray 0.75 μg, 1.0 μg, or 1.5 μg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>South Korea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010 to 2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged ≥ 50 years with LUTS due to bladder outlet obstruction (Q<sub>max</sub> ≤ 15 mL/second, IPSS ≥ 14) and nocturia (≥ 1 void/night) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin 0.2 mg oral + tamsulosin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: solifenacin + tamsulosin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single centre/Taiwan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2007 to 2009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged ≥ 65 years with BPH (IPSS &gt; 13), nocturia (≥ 2 voids/night), and nocturnal polyuria (nocturnal urine volume &gt; 30%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin 0.1 mg oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0011" title="WangW , ChenS . Low dose oral desmopressin in treatment of nocturia in elderly men. Urology2012;80(3 Suppl):S117. [DOI: 10.1016/S0090‐4295(12)00880‐1] ">Wang 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient/single centre/China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2009 to 2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Older men (age not reported)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin 0.1 mg oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre/Canada and the USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2007 to 2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men and women aged ≥ 18 years with nocturia (≥ 2 voids/night)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin 10 µg, 25 µg, 50 µg, or 100 µg ODT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre/Canada and the USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010 to 2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged ≥ 18 years with nocturia (≥ 2 voids/night)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin 50 μg, 75 µg ODT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre/Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010 to 2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men and women aged 55 to 75 years with nocturia (≥ 2 voids/night)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin 10 µg, 25 µg, 50 µg, or 100 µg ODT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BPH: benign prostatic hyperplasia; C: comparator; I: intervention; IPSS: International Prostate Symptom Score; LUTS: lower urinary tract symptoms; NPI: nocturnal polyuria index; NR: not reported; ODT: orally disintegrating tablet; Q<sub>max</sub>: maximum flow rate. </p> </div> </div> <div class="table" id="CD012059-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participant disposition</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sample size</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Screened/eligible<br/> (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised<br/> (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ITT<br/> (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analysed<br/> (n: total/male)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Finishing trial<br/> (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised finishing trial<br/> (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up<br/> (extended follow‐up)<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] "><b>Ahmed 2015a</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin + tamsulosin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>397/273</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: tamsulosin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>273</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012059-bbs2-0002" title="CannonA , CarterPG , McConnellAA , AbramsP . Desmopressin in the treatment of nocturnal polyuria in the male. BJU International1999;84(1):20‐4. [PUBMED: 10444118 ] "><b>Cannon 1999</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐/‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>8 weeks (cross‐over study design)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] "><b>Ceylan 2013</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>84/31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: doxazosin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '><b>Kim 2017</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin + alpha‐blocker</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>121/109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>8 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + alpha‐blocker</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] "><b>Koca 2012</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin + alfuzosin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐/49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: alfuzosin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] "><b>Mattiasson 2002</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>341/224</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] "><b>Rezakhaniha 2011</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>93/60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>8 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a><b><sup>2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: desmopressin 0.75 μg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3565/1707</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>448</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>448/252</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>401</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: desmopressin 1.0 μg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183/109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I3: desmopressin 1.5 μg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>452</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>439</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>439/251</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>387</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>446</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>446/258</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>408</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1556</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1516</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1516/870</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1359</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] "><b>Shin 2014a</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin + tamsulosin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>435/427</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>8 weeks (cross‐over study design)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: tamsulosin + solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>209</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>427</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>427</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>427</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>405</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] "><b>Wang 2011a</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐/136</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012059-bbs2-0011" title="WangW , ChenS . Low dose oral desmopressin in treatment of nocturia in elderly men. Urology2012;80(3 Suppl):S117. [DOI: 10.1016/S0090‐4295(12)00880‐1] "><b>Wang 2012</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐/60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>8 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a><b><sup>2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: desmopressin 10 µg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>1412/799</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155/82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>4 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: desmopressin 25 µg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152/87</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I3: desmopressin 50 µg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148/77</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I4: desmopressin 100 µg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146/80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156/90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>799</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>757</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>757/416</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>710</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] "><b>Weiss 2013</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: desmopressin 50 µg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>1013/395</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: desmopressin 75 µg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>395</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>385</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>385</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>323</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a><b><sup>2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: desmopressin 10 µg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>177/139</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: desmopressin 25 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I3: desmopressin 50 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I4: desmopressin 100 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112/54</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Overall total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Men</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2966</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="3" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1045</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4195</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4011</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>‐ denotes not reported; C: comparator; I: intervention; ITT: intention‐to‐treat; n: number of participants. </p> <p><sup>1</sup>Follow‐up under randomised conditions until end of trial or if not available, duration of intervention; extended follow‐up refers to follow‐up of participants once the original study was terminated as specified in the power calculation.<br/> <sup>2</sup>Study included men and women. </p> </div> </div> <section id="CD012059-sec-0079"> <h5 class="title">Source of data</h5> <p>The literature search identified all 14 trials included in the review. Of the 14 included studies, we found one study by the New Drug Application submitted to the FDA (<a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>), and the remaining studies were published trials. We contacted all trial authors of the included trials except two studies supported by pharmaceutical companies (<a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). We received a reply from six trial authors (<a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] ">Rezakhaniha 2011</a>; <a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>). </p> </section> <section id="CD012059-sec-0080"> <h5 class="title">Study design and settings</h5> <p>Two trials were cross‐over randomised controlled trials (<a href="./references#CD012059-bbs2-0002" title="CannonA , CarterPG , McConnellAA , AbramsP . Desmopressin in the treatment of nocturnal polyuria in the male. BJU International1999;84(1):20‐4. [PUBMED: 10444118 ] ">Cannon 1999</a>; <a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a>). The remaining studies were parallel‐group randomised controlled trials (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a>; <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>; <a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] ">Rezakhaniha 2011</a>; <a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>; <a href="./references#CD012059-bbs2-0011" title="WangW , ChenS . Low dose oral desmopressin in treatment of nocturia in elderly men. Urology2012;80(3 Suppl):S117. [DOI: 10.1016/S0090‐4295(12)00880‐1] ">Wang 2012</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). One trial was single‐blinded (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>). Four trials were reported as double‐blinded, and stated that participants and investigators were blinded (<a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). Three trials were reported to be double‐blinded, but it was unclear which groups were actually blinded (<a href="./references#CD012059-bbs2-0002" title="CannonA , CarterPG , McConnellAA , AbramsP . Desmopressin in the treatment of nocturnal polyuria in the male. BJU International1999;84(1):20‐4. [PUBMED: 10444118 ] ">Cannon 1999</a>; <a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>). The lead author of <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a> confirmed that participants and personnel were blinded. Five trials provided no information regarding blinding (<a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a>; <a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>; <a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] ">Rezakhaniha 2011</a>; <a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a>; <a href="./references#CD012059-bbs2-0011" title="WangW , ChenS . Low dose oral desmopressin in treatment of nocturia in elderly men. Urology2012;80(3 Suppl):S117. [DOI: 10.1016/S0090‐4295(12)00880‐1] ">Wang 2012</a>). Four trials had run‐in periods (<a href="./references#CD012059-bbs2-0002" title="CannonA , CarterPG , McConnellAA , AbramsP . Desmopressin in the treatment of nocturnal polyuria in the male. BJU International1999;84(1):20‐4. [PUBMED: 10444118 ] ">Cannon 1999</a>; <a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a>). None of the trials were terminated early (for benefit). </p> <p>All studies were likely conducted in an outpatient urology clinic setting. Five of 14 trials explicitly stated that the trial was conducted in an outpatient urology clinic setting (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a>; <a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>; <a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] ">Rezakhaniha 2011</a>; <a href="./references#CD012059-bbs2-0011" title="WangW , ChenS . Low dose oral desmopressin in treatment of nocturia in elderly men. Urology2012;80(3 Suppl):S117. [DOI: 10.1016/S0090‐4295(12)00880‐1] ">Wang 2012</a>). Six trials were multicentre studies (<a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). Seven trials were performed in Asia (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] ">Rezakhaniha 2011</a>; <a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a>; <a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>; <a href="./references#CD012059-bbs2-0011" title="WangW , ChenS . Low dose oral desmopressin in treatment of nocturia in elderly men. Urology2012;80(3 Suppl):S117. [DOI: 10.1016/S0090‐4295(12)00880‐1] ">Wang 2012</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>), and the remaining studies were conducted in Europe and the USA. Trials were performed during the time frame of 1999 to 2016. Thirteen trials were published in English, and one was published in Turkish (<a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>), which was translated into English using Google Translate. </p> </section> <section id="CD012059-sec-0081"> <h5 class="title">Participants</h5> <p>This review included a total of 4195 randomised participants (range 20 to 1556), of which a total of 4011 were subsequently accounted for in the analysis. Of the 4011 participants, 1045 were women (26.0%), as three trials included women (<a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). The ethnic group representation was clearly reported in only one trial (<a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>: 78.4% white; 12.1% African‐American; 2% Asian; 6.6% Hispanic and others). The mean age of the men ranged from 57 to 74 years; four studies did not report age (<a href="./references#CD012059-bbs2-0002" title="CannonA , CarterPG , McConnellAA , AbramsP . Desmopressin in the treatment of nocturnal polyuria in the male. BJU International1999;84(1):20‐4. [PUBMED: 10444118 ] ">Cannon 1999</a>; <a href="./references#CD012059-bbs2-0011" title="WangW , ChenS . Low dose oral desmopressin in treatment of nocturia in elderly men. Urology2012;80(3 Suppl):S117. [DOI: 10.1016/S0090‐4295(12)00880‐1] ">Wang 2012</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). One trial reported the mean prostate volume, which was 45.7 mL for the treatment group and 47.0 mL for the comparator group (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>). Two trials reported mean prostate specific antigen, which ranged from 1.8 ng/mL to 2.6 ng/mL (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a>). Five studies reported mean baseline IPSS score, peak urinary flow rate, and postvoid residual (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a>; <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>; <a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a>). Mean baseline IPSS score ranged from 12.1 to 24.9. Mean baseline maximum flow rate (Q<sub>max</sub>) ranged from 10.3 mL/second to 17.8 mL/second. The mean baseline postvoid residual ranged from 32.9 mL to 61.8 mL. The mean IPSS score after intervention ranged from 6.5 to 23.2. The mean Q<sub>max</sub> after intervention ranged from 13.3 mL/second to 22.7 mL/second. The mean postvoid residual after intervention ranged from 14.0 mL to 41.4 mL. </p> <p>Eleven of 14 studies included participants aged over 40 years, <a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0002" title="CannonA , CarterPG , McConnellAA , AbramsP . Desmopressin in the treatment of nocturnal polyuria in the male. BJU International1999;84(1):20‐4. [PUBMED: 10444118 ] ">Cannon 1999</a>; <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>; <a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a>; <a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>, or with old age (not defined; <a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a>; <a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] ">Rezakhaniha 2011</a>; <a href="./references#CD012059-bbs2-0011" title="WangW , ChenS . Low dose oral desmopressin in treatment of nocturia in elderly men. Urology2012;80(3 Suppl):S117. [DOI: 10.1016/S0090‐4295(12)00880‐1] ">Wang 2012</a>). Three trials included participants aged over 18 years (<a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>). Three trials included men and women and reported the men's data separately (<a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). </p> <p>Major exclusion criteria from trials included prior treatment with desmopressin or other BPH medical therapy within three months, evidence of severe daytime voiding dysfunction, suspicion of bladder outlet obstruction or a urine flow less than 5 mL/second, prior genitourinary surgeries, urinary retention or elevated postvoid residual greater than 250 mL (or both), history of genitourinary malignancies, positive urine cultures, hyponatraemia, uncontrolled diabetes, uncontrolled hypertension, diuretic use, voiding dysfunctions arising from well‐defined causes other than BPH, or polydipsia. For the two of three trials that included women (<a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>), potential for pregnancy, use of a pessary or pelvic prolapse, and presence of an unexplained pelvic mass were exclusion criteria. </p> </section> <section id="CD012059-sec-0082"> <h5 class="title">Diagnosis</h5> <p>Most studies defined nocturia as two or more voids per night (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a>; <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>; <a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] ">Rezakhaniha 2011</a>; <a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>), and only one study used one or more voids per night as an inclusion criterion (<a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a>). Two trials did not report a definition of nocturia (<a href="./references#CD012059-bbs2-0002" title="CannonA , CarterPG , McConnellAA , AbramsP . Desmopressin in the treatment of nocturnal polyuria in the male. BJU International1999;84(1):20‐4. [PUBMED: 10444118 ] ">Cannon 1999</a>; <a href="./references#CD012059-bbs2-0011" title="WangW , ChenS . Low dose oral desmopressin in treatment of nocturia in elderly men. Urology2012;80(3 Suppl):S117. [DOI: 10.1016/S0090‐4295(12)00880‐1] ">Wang 2012</a>). Four trials only included participants with nocturnal polyuria defined as the overproduction of urine at night (i.e. excess of a third or 30% of total daily urine volume; <a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0002" title="CannonA , CarterPG , McConnellAA , AbramsP . Desmopressin in the treatment of nocturnal polyuria in the male. BJU International1999;84(1):20‐4. [PUBMED: 10444118 ] ">Cannon 1999</a>; <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>). </p> </section> <section id="CD012059-sec-0083"> <h5 class="title">Interventions and comparators</h5> <p>Three included studies administered desmopressin as a nasal spray (<a href="./references#CD012059-bbs2-0002" title="CannonA , CarterPG , McConnellAA , AbramsP . Desmopressin in the treatment of nocturnal polyuria in the male. BJU International1999;84(1):20‐4. [PUBMED: 10444118 ] ">Cannon 1999</a>; <a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a>; <a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>), while the remaining 11 studies administered an oral or sublingual formulation. Two studies used desmopressin 20 μg nasal spray (<a href="./references#CD012059-bbs2-0002" title="CannonA , CarterPG , McConnellAA , AbramsP . Desmopressin in the treatment of nocturnal polyuria in the male. BJU International1999;84(1):20‐4. [PUBMED: 10444118 ] ">Cannon 1999</a>; <a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a>), and one trial used a new formulation of nasal spray submitted for FDA approval with a desmopressin dose ranging from 0.75 μg to 1.5 μg (<a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>). Four trials administered desmopressin as a sublingual agent (orally disintegrating tablet), with a dose range from 10 μg to 100 μg (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). The remaining studies administered desmopressin as an oral agent (dose range from 0.1 mg to 0.4 mg). Three studies included participants given sublingual desmopressin less than the clinical dosage (60 μg) as an experimental group (<a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>: 10/25/50 μg, <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>: 50 μg, <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>: 10/25/50 μg). Ten of 14 studies used desmopressin as monotherapy (<a href="./references#CD012059-bbs2-0002" title="CannonA , CarterPG , McConnellAA , AbramsP . Desmopressin in the treatment of nocturnal polyuria in the male. BJU International1999;84(1):20‐4. [PUBMED: 10444118 ] ">Cannon 1999</a>; <a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a>; <a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] ">Rezakhaniha 2011</a>; <a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>; <a href="./references#CD012059-bbs2-0011" title="WangW , ChenS . Low dose oral desmopressin in treatment of nocturia in elderly men. Urology2012;80(3 Suppl):S117. [DOI: 10.1016/S0090‐4295(12)00880‐1] ">Wang 2012</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). Four trials investigated the combination of desmopressin with alpha‐blocker therapy (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>; <a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a>). One study had dose titration of desmopressin prior to randomisation, and only participants who obtained a 20% reduction in nocturnal diuresis were enrolled in the study (active run‐in; <a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>). </p> <p>Comparators were behaviour modification and four agents, namely placebo, alpha‐blocker, desmopressin plus alpha‐blocker, and desmopressin plus anticholinergic. Placebo was administered in accordance with the frequencies of desmopressin administration (<a href="./references#CD012059-bbs2-0002" title="CannonA , CarterPG , McConnellAA , AbramsP . Desmopressin in the treatment of nocturnal polyuria in the male. BJU International1999;84(1):20‐4. [PUBMED: 10444118 ] ">Cannon 1999</a>; <a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] ">Rezakhaniha 2011</a>; <a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). <a href="./references#CD012059-bbs2-0011" title="WangW , ChenS . Low dose oral desmopressin in treatment of nocturia in elderly men. Urology2012;80(3 Suppl):S117. [DOI: 10.1016/S0090‐4295(12)00880‐1] ">Wang 2012</a> encouraged liquid restriction during nighttime for participants in the control group. A variety of alpha‐blockers (alfuzosin, doxazosin, and tamsulosin) were administered orally as monotherapy, <a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a>; <a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>, and combination therapy with placebo, <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>, or anticholinergic, <a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a>. Alfuzosin (10 mg; <a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>), doxazosin (2 mg or 4 mg; <a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a>), and tamsulosin (0.2 mg or 0.4 mg; <a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a>) were used as comparator drug agents. Solifenacin (5 mg; <a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a>) was used as a comparator in combination therapy with an alpha‐blocker. </p> <p>The duration of interventions ranged from three weeks to 12 months. All included studies reported short‐term outcomes across five comparisons. Only one study reported intermediate‐term outcomes for the comparison of desmopressin versus placebo (<a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>). No studies reported long‐term follow‐up. </p> </section> <section id="CD012059-sec-0084"> <h5 class="title">Comparisons</h5> <p>We included five comparisons in this review, of which eight studies compared desmopressin to placebo (<a href="./references#CD012059-bbs2-0002" title="CannonA , CarterPG , McConnellAA , AbramsP . Desmopressin in the treatment of nocturnal polyuria in the male. BJU International1999;84(1):20‐4. [PUBMED: 10444118 ] ">Cannon 1999</a>; <a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] ">Rezakhaniha 2011</a>; <a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). One study compared desmopressin to behavioural modifications (<a href="./references#CD012059-bbs2-0011" title="WangW , ChenS . Low dose oral desmopressin in treatment of nocturia in elderly men. Urology2012;80(3 Suppl):S117. [DOI: 10.1016/S0090‐4295(12)00880‐1] ">Wang 2012</a>). One study compared desmopressin to an alpha‐blocker (<a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a>). Three studies compared the addition of desmopressin to alpha‐blocker therapy versus an alpha‐blocker alone (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>). One study compared desmopressin with an alpha‐blocker to an alpha‐blocker with an anticholinergic (<a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a>). No trials compared desmopressin to surgery. </p> </section> <section id="CD012059-sec-0085"> <h5 class="title">Outcomes</h5> <p>We identified all primary outcomes in each of the included studies for four comparisons. The number of nocturnal voids and major adverse events were reported in all comparisons except desmopressin versus behaviour modification. Quality of life outcomes were reported in the comparisons of desmopressin versus alpha‐blocker and desmopressin plus alpha‐blocker versus alpha‐blocker. Eight trials reported health‐related quality of life using the IPSS (<a href="https://archie.cochrane.org/sections/documents/view?document=z1411252325181805391402826796432%26format=REVMAN#STD-Ahmed-2015a" target="_blank">Ahmed 2015a</a>; <a href="https://archie.cochrane.org/sections/documents/view?document=z1411252325181805391402826796432%26format=REVMAN#STD-Ceylan-2013" target="_blank">Ceylan 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?document=z1411252325181805391402826796432%26format=REVMAN#STD-Kim-2017" target="_blank">Kim 2017</a>; <a href="https://archie.cochrane.org/sections/documents/view?document=z1411252325181805391402826796432%26format=REVMAN#STD-Koca-2012" target="_blank">Koca 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?document=z1411252325181805391402826796432%26format=REVMAN#STD-Shin-2014a" target="_blank">Shin 2014a</a>; <a href="https://archie.cochrane.org/sections/documents/view?document=z1411252325181805391402826796432%26format=REVMAN#STD-Wang-2011a" target="_blank">Wang 2011a</a>; <a href="https://archie.cochrane.org/sections/documents/view?document=z1411252325181805391402826796432%26format=REVMAN#STD-Weiss-2012a" target="_blank">Weiss 2012a</a>; <a href="https://archie.cochrane.org/sections/documents/view?document=z1411252325181805391402826796432%26format=REVMAN#STD-Weiss-2013" target="_blank">Weiss 2013</a>). We were able to use the information regarding quality of life outcomes for the comparisons of desmopressin versus alpha‐blocker and desmopressin plus alpha‐blocker versus alpha‐blocker. The authors of included studies did not use validated score systems such as Common Terminology Criteria for Adverse Events to assess adverse events (<a href="./references#CD012059-bbs2-0071" title="National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm (accessed 8 September 2017). ">National Cancer Institute</a>), therefore we judged the severity of adverse events using the available information described in the studies. </p> <p>For secondary outcomes, the duration of the first sleep episode was reported in the comparisons of desmopressin versus placebo and desmopressin versus behaviour modification. None of the studies reported time to first void. The outcomes of minor adverse events and treatment withdrawal due to adverse event were reported in all comparisons except desmopressin versus behaviour modification. </p> </section> <section id="CD012059-sec-0086"> <h5 class="title">Funding source and conflicts of interest</h5> <p>Seven studies specified funding sources (<a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] ">Rezakhaniha 2011</a>; <a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>): five were supported by pharmaceutical companies; one was funded by government; and one reported no funding source. Six studies reported no conflicts of interest (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a>; <a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>; <a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] ">Rezakhaniha 2011</a>; <a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a>), and five reported having relationships with pharmaceutical companies (<a href="./references#CD012059-bbs2-0002" title="CannonA , CarterPG , McConnellAA , AbramsP . Desmopressin in the treatment of nocturnal polyuria in the male. BJU International1999;84(1):20‐4. [PUBMED: 10444118 ] ">Cannon 1999</a>; <a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). </p> </section> </section> <section id="CD012059-sec-0087"> <h4 class="title">Excluded studies</h4> <p>We excluded 17 studies (18 articles) after evaluation of the full publication (see <a href="./references#CD012059-sec-0232" title="">Characteristics of excluded studies</a> table). Six studies were duplicates (<a href="./references#CD012059-bbs2-0015" title="AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015b</a>; <a href="./references#CD012059-bbs2-0018" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] '>Cho 2016</a>; <a href="./references#CD012059-bbs2-0022" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] ">Kaminetsky 2016</a>; <a href="./references#CD012059-bbs2-0027" title="ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [DOI: 10.2147/CIA.S64194] ">Shin 2014b</a>; <a href="./references#CD012059-bbs2-0029" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011b</a>; <a href="./references#CD012059-bbs2-0030" title="WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21:S285‐7. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] ">Weiss 2012b</a>). Four studies had the wrong study design (<a href="./references#CD012059-bbs2-0020" title="GilbertE , WahlquistAH . Oral desmopressin effective for nocturnal polyuria in men with benign prostatic hyperplasia. Journal of the National Medical Association2011;103(5):461. [DOI: 10.1016/S0027‐9684(15)30347‐3] ">Gilbert 2011</a>; <a href="./references#CD012059-bbs2-0021" title="Holm‐LarsenT , DijkD , BlemingsA , JuulKV . Kaplan‐Meier survival analysis indicates improved undisturbed initial sleep in nocturia patients treated with desmopressin. Sleep2013;36:A296. ">Holm‐Larsen 2013a</a>; <a href="./references#CD012059-bbs2-0025" title="MoonDG , KoYH , JinMH , KimJJ . Effects of desmopressin on nocturia in adult. Journal of Urology2002;167(Suppl 4):267. ">Moon 2002</a>; <a href="./references#CD012059-bbs2-0026" title="MoonDG , KongSH , CheonJ , LeeJG , KimJJ . Antidiuretic hormone in adult nocturia. Journal of Urology2003;169(Suppl 4):334. [DOI: 10.1016/S0022‐5347(03)80069‐1] ">Moon 2003</a>). Four studies had the wrong study population (<a href="./references#CD012059-bbs2-0016" title="AsplundR , SundbergB , BengtssonP . Oral desmopressin for nocturnal polyuria in elderly subjects: a double‐blind, placebo‐controlled randomized exploratory study. BJU International1999;83(6):591‐5. [PUBMED: 10233563 ] ">Asplund 1999</a>; <a href="./references#CD012059-bbs2-0023" title="LamYC , ChanCK , CheungFK . Efficacy and safety of minirin melt in elderly with nocturia ‐ a randomized double‐blinded placebo controlled trial. International Journal of Urology2017;24(Suppl 1):23. [DOI: 10.1111/iju.13413] ">Lam 2017</a>; <a href="./references#CD012059-bbs2-0028" title="vanKerrebroeckP , RezapourM , CortesseA , ThuroffJ , RiisA , NorgaardJP . Desmopressin in the treatment of nocturia: a double‐blind, placebo‐controlled study. European Urology2007;52(1):221‐9. [DOI: 10.1016/j.eururo.2007.01.027] ">van Kerrebroeck 2007</a>; <a href="./references#CD012059-bbs2-0031" title="YassinA , SaadF , HaiderA . Oral desmopressin in the treatment of nocturia in an aging population. Urology2010;3 Suppl:S40‐1. [DOI: 10.1016/j.urology.2010.07.435] ">Yassin 2010</a>). Of the remaining studies, one had the wrong intervention (<a href="./references#CD012059-bbs2-0019" title="FuF , LaveryHJ , WuDL . Reducing nocturia in the elderly: a randomized placebo‐controlled trial of staggered furosemide and desmopressin. Neurourology and Urodynamics2011;30(3):312‐6. [PUBMED: 21305590 ] ">Fu 2011</a>); one had the wrong comparator (<a href="./references#CD012059-bbs2-0017" title="ChoSY , ParkJ , PiaoS , LeeSB , ChunJY , JeongH , et al. The effect of combined systematized behavioral modification education program (SBMP) with DDAVP in patients with nocturia: a multicenter, randomized, and parallel study. European Urology Supplements2015;14(2):e689‐e689b. [DOI: 10.1016/S1569‐9056(15)60681‐9] ">Cho 2015</a>); and one had the wrong outcome (<a href="./references#CD012059-bbs2-0024" title="MalliD , MorkunaiteD , GobleS , AndersonP , Holm‐LarsenT . QOL in patients with nocturia: does the study design impact the outcome?. Neurourology and Urodynamics2014;33(6):784‐6. [DOI: 10.1002/nau.22655] ">Malli 2014</a>). </p> <section id="CD012059-sec-0088"> <h5 class="title">Studies awaiting classification</h5> <p>There are four studies awaiting classification (see <a href="./references#CD012059-sec-0233" title="">Characteristics of studies awaiting classification</a> table) (<a href="./references#CD012059-bbs2-0032" title="Holm‐LarsenT , AnderssonF , YankovV , NorgaardJP . One month after treatment initiation nocturia patients slept significantly longer and better on treatment than placebo patients. Value in Health2013;16(3):A183. ">Holm‐Larsen 2013b</a>; <a href="./references#CD012059-bbs2-0033" title="NCT01694498 . A randomised, double‐blind, placebo‐controlled, parallel‐group, multi‐centre trial investigating the efficacy and safety of two different dose levels of desmopressin for the treatment of nocturia in adult men. clinicaltrials.gov/ct2/show/NCT01694498 (date first received 30 August 2017). ">NCT01694498</a>; <a href="./references#CD012059-bbs2-0034" title="SalvatoreS , HillS , CardozoL , KhullarV , AndersK , GleesonC . A double‐blind, placebo‐controlled trial of oral desmopressin in patients with nocturia. 26th Annual Meeting of the International Continence Society; 1996 Aug 27‐30; Athens, Greece1996. ">Salvatore 1996</a>; <a href="./references#CD012059-bbs2-0035" title="WeissJ , BlaivasJG , AbramsP , MattiassonA , RobertsonG , vanKerrebroeckP , et al. Oral desmopressin (Minirin, DDAVP) in the treatment of nocturia in men. Journal of Urology2001;165(5 Suppl):250. ">Weiss 2001</a>). </p> </section> <section id="CD012059-sec-0089"> <h5 class="title">Ongoing studies</h5> <p>We found one ongoing study (see <a href="./references#CD012059-sec-0234" title="">Characteristics of ongoing studies</a> table) (<a href="./references#CD012059-bbs2-0036" title="NCT02904759 . Trial of desmopressin orally disintegrating tablets (ODT) for nocturia due to nocturnal polyuria in Japanese male subjects. clinicaltrials.gov/ct2/show/NCT02904759 (date first received 30 August 2017). ">NCT02904759</a>). </p> </section> </section> </section> <section id="CD012059-sec-0090"> <h3 class="title">Risk of bias in included studies</h3> <p>Detailed results of the 'Risk of bias' assessment are provided in <a href="#CD012059-fig-0002">Figure 2</a> and <a href="#CD012059-fig-0003">Figure 3</a>, and judgements for individual domains are provided in the <a href="./references#CD012059-sec-0231" title="">Characteristics of included studies</a> table. </p> <div class="figure" id="CD012059-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD012059-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD012059-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies." data-id="CD012059-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD012059-sec-0091"> <h4 class="title">Allocation</h4> <section id="CD012059-sec-0092"> <h5 class="title">Random sequence generation</h5> <p>The sequence generation for participation allocation was adequate in six trials and rated at low risk of bias (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). In the remaining trials, the method of sequence generation was unclear or not specified. </p> </section> <section id="CD012059-sec-0093"> <h5 class="title">Allocation concealment</h5> <p>Two trials had adequate allocation concealment and were at low risk of bias (<a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>). In the remaining trials, treatment allocation was unclear. </p> </section> </section> <section id="CD012059-sec-0094"> <h4 class="title">Blinding</h4> <section id="CD012059-sec-0095"> <h5 class="title">Blinding of participants and personnel</h5> <p>Five trials were at low risk of bias (<a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>), and one study was at high risk of bias (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>). The remaining studies were at unclear risk of bias. </p> </section> <section id="CD012059-sec-0096"> <h5 class="title">Blinding of outcome assessment</h5> <p>Five studies were at low risk of bias (<a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). The remaining studies were at unclear risk of bias. </p> </section> </section> <section id="CD012059-sec-0097"> <h4 class="title">Incomplete outcome data</h4> <section id="CD012059-sec-0098"> <h5 class="title">Number of nocturnal voids</h5> <p>Nine trials were at low risk of bias for number of nocturnal voids (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>; <a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] ">Rezakhaniha 2011</a>; <a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a>; <a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>; <a href="./references#CD012059-bbs2-0011" title="WangW , ChenS . Low dose oral desmopressin in treatment of nocturia in elderly men. Urology2012;80(3 Suppl):S117. [DOI: 10.1016/S0090‐4295(12)00880‐1] ">Wang 2012</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>). Three studies were at high risk of bias (<a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a>; <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). The remaining studies were at unclear risk of bias. </p> </section> <section id="CD012059-sec-0099"> <h5 class="title">Quality of life</h5> <p>Four trials were at low risk of bias (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>; <a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>; <a href="./references#CD012059-bbs2-0011" title="WangW , ChenS . Low dose oral desmopressin in treatment of nocturia in elderly men. Urology2012;80(3 Suppl):S117. [DOI: 10.1016/S0090‐4295(12)00880‐1] ">Wang 2012</a>). Three studies were at high risk of bias (<a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a>; <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). The remaining studies were at unclear risk of bias. </p> </section> <section id="CD012059-sec-0100"> <h5 class="title">Duration of first sleep episode</h5> <p>Five trials were at low risk of bias (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] ">Rezakhaniha 2011</a>; <a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>; <a href="./references#CD012059-bbs2-0011" title="WangW , ChenS . Low dose oral desmopressin in treatment of nocturia in elderly men. Urology2012;80(3 Suppl):S117. [DOI: 10.1016/S0090‐4295(12)00880‐1] ">Wang 2012</a>). Three studies were at high risk of bias (<a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a>; <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). The remaining studies were at unclear risk of bias. </p> </section> <section id="CD012059-sec-0101"> <h5 class="title">Time to first void</h5> <p>Two studies were at low risk of bias (<a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>). One study was at high risk of bias (<a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a>). The remaining (11 of 14) studies were at unclear risk of bias. </p> </section> <section id="CD012059-sec-0102"> <h5 class="title">Major adverse events, minor adverse events, and treatment withdrawal due to adverse event </h5> <p>Most studies (eight of 14) were at low risk of bias (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>; <a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] ">Rezakhaniha 2011</a>; <a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a>; <a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>). Two studies were at high risk of bias (<a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a>; <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>). The remaining studies were at unclear risk of bias. </p> </section> </section> <section id="CD012059-sec-0103"> <h4 class="title">Selective reporting</h4> <p>We identified published protocols for four included studies and rated the risk of reporting bias for these studies as low (<a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). Although there was a published protocol for a fifth study, we rated this study as at high risk of reporting bias due to important deficits in outcome reporting (<a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>). One study did not have a published protocol, but we rated it at low risk of bias due to its comprehensive outcome reporting (<a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a>). We judged the risk of selective reporting bias as unclear for the remaining studies. </p> </section> <section id="CD012059-sec-0104"> <h4 class="title">Other potential sources of bias</h4> <p>We rated eight trials as at low risk of bias (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a>; <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>; <a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] ">Rezakhaniha 2011</a>; <a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a>; <a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>). We rated one study as at high risk of bias due to the exclusion of participants who did not respond in the active run‐in period (<a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>). The remaining five trials were at unclear risk of bias: two trials had placebo or active run‐in periods (<a href="./references#CD012059-bbs2-0002" title="CannonA , CarterPG , McConnellAA , AbramsP . Desmopressin in the treatment of nocturnal polyuria in the male. BJU International1999;84(1):20‐4. [PUBMED: 10444118 ] ">Cannon 1999</a>; <a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>); three trials had a participant population that consisted of almost 50% women (which we were able to selectively exclude from the analysis); we noted that the investigators did not stratify randomisation based on gender, which may have resulted in prognostic imbalances (<a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>); and one trial, reported as abstract only, had insufficient information to assess for other biases and was rated as at unclear risk of bias (<a href="./references#CD012059-bbs2-0011" title="WangW , ChenS . Low dose oral desmopressin in treatment of nocturia in elderly men. Urology2012;80(3 Suppl):S117. [DOI: 10.1016/S0090‐4295(12)00880‐1] ">Wang 2012</a>). </p> </section> </section> <section id="CD012059-sec-0105"> <h3 class="title" id="CD012059-sec-0105">Effects of interventions</h3> <p>See: <a href="./full#CD012059-tbl-0001"><b>Summary of findings for the main comparison</b> Desmopressin versus placebo for men with nocturia (short term)</a>; <a href="./full#CD012059-tbl-0002"><b>Summary of findings 2</b> Desmopressin versus placebo for men with nocturia (intermediate term)</a>; <a href="./full#CD012059-tbl-0003"><b>Summary of findings 3</b> Desmopressin versus behaviour modifications for men with nocturia (short term)</a>; <a href="./full#CD012059-tbl-0004"><b>Summary of findings 4</b> Desmopressin versus alpha‐blocker for men with nocturia (short term)</a>; <a href="./full#CD012059-tbl-0005"><b>Summary of findings 5</b> Desmopressin plus alpha‐blocker versus alpha‐blocker for men with nocturia (short term)</a>; <a href="./full#CD012059-tbl-0006"><b>Summary of findings 6</b> Desmopressin plus alpha‐blocker versus alpha‐blocker plus anticholinergic for men with nocturia (short term)</a> </p> <section id="CD012059-sec-0106"> <h4 class="title">Desmopressin versus placebo</h4> <p>We included eight studies comparing desmopressin versus placebo with short‐term follow‐up (<a href="./references#CD012059-bbs2-0002" title="CannonA , CarterPG , McConnellAA , AbramsP . Desmopressin in the treatment of nocturnal polyuria in the male. BJU International1999;84(1):20‐4. [PUBMED: 10444118 ] ">Cannon 1999</a>; <a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] ">Rezakhaniha 2011</a>; <a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>; <a href="./full#CD012059-tbl-0001">summary of findings Table for the main comparison</a>), and one study with intermediate‐term follow‐up in this comparison (<a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>; <a href="./full#CD012059-tbl-0002">summary of findings Table 2</a>). There were no studies with long‐term follow‐up. </p> <section id="CD012059-sec-0107"> <h5 class="title">Primary outcomes</h5> <section id="CD012059-sec-0108"> <h6 class="title">1. Number of nocturnal voids</h6> <p>We included six studies with 1982 men (intervention 1360, control 622) for short‐term follow‐up (<a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). Desmopressin may result in a small, possibly unimportant effect on the number of nocturnal voids (mean difference (MD) ‐0.61, 95% confidence interval (CI) ‐0.96 to ‐0.27) (<a href="./references#CD012059-fig-0004" title="">Analysis 1.1</a>). We rated the quality of evidence as low according to GRADE, downgrading for study limitations and inconsistency. </p> <p>We included one study with 115 men (intervention 57, control 58) for intermediate‐term follow‐up (<a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>). Desmopressin may reduce the number of nocturnal voids in an appreciable number of men (MD ‐0.85, 95% CI ‐1.17 to ‐0.53) (<a href="./references#CD012059-fig-0005" title="">Analysis 1.2</a>). We rated the quality of evidence as low according to GRADE, downgrading for study limitations and imprecision. </p> </section> <section id="CD012059-sec-0109"> <h6 class="title">2. Quality of life</h6> <p>None of the included studies reported quality of life.</p> </section> <section id="CD012059-sec-0110"> <h6 class="title">3. Major adverse events</h6> <p>We included two studies with 536 men (intervention 329, control 207) for short‐term follow‐up (<a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>). We are uncertain about the effect of desmopressin on major adverse events (risk ratio (RR) 0.97, 95% CI 0.10 to 9.03) (<a href="./references#CD012059-fig-0006" title="">Analysis 1.3</a>). We rated the quality of evidence as very low according to GRADE, downgrading for study limitations, inconsistency, and imprecision. </p> <p>We included one study with 115 men (intervention 57, control 58) for intermediate‐term follow‐up (<a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>). Desmopressin may result in little or no difference in major adverse events (RR 3.05, 95% CI 0.13 to 73.39) (<a href="./references#CD012059-fig-0007" title="">Analysis 1.4</a>). We rated the quality of evidence as low according to GRADE, downgrading for study limitations and imprecision. </p> </section> </section> <section id="CD012059-sec-0111"> <h5 class="title">Secondary outcomes</h5> <section id="CD012059-sec-0112"> <h6 class="title">1. Duration of first sleep episode</h6> <p>We included four studies with 652 men (intervention 443, control 209) for short‐term follow‐up (<a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). Desmopressin may improve the duration of first sleep episode, but we are very uncertain of this finding (MD 54.61 minutes, 95% CI 13.97 to 95.25) (<a href="./references#CD012059-fig-0008" title="">Analysis 1.5</a>). We rated the quality of evidence as very low according to GRADE, downgrading for study limitations, inconsistency, and imprecision. </p> <p>We included one study with 115 men (intervention 57, control 58) for intermediate‐term follow‐up (<a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>). Desmopressin likely results in a small effect, but this may not represent a clinically important improvement in the duration of first sleep episode (MD 18.4 minutes, 95% CI 11.6 to 25.2) (<a href="./references#CD012059-fig-0009" title="">Analysis 1.6</a>). We rated the quality of evidence as moderate according to GRADE, downgrading for study limitations. </p> </section> <section id="CD012059-sec-0113"> <h6 class="title">2. Time to first void</h6> <p>We included one study with 383 men (intervention 241, control 142) for short‐term follow‐up (<a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>). Desmopressin may result in a small, possibly unimportant effect on time to first void (MD 40.80, 95% CI 17.07 to 64.53) (<a href="./references#CD012059-fig-0010" title="">Analysis 1.7</a>). We rated the quality of evidence as low according to GRADE, downgrading for study limitations and imprecision. </p> </section> <section id="CD012059-sec-0114"> <h6 class="title">3. Minor adverse events</h6> <p>We included three studies with 594 men (intervention 357, control 237) for short‐term follow‐up (<a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] ">Rezakhaniha 2011</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>). Desmopressin may result in little or no difference in minor adverse events (RR 0.87, 95% CI 0.67 to 1.13) (<a href="./references#CD012059-fig-0011" title="">Analysis 1.8</a>). We rated the quality of evidence as low according to GRADE, downgrading for study limitations and imprecision. </p> <p>We included one study with 115 men (intervention 57, control 58) for intermediate‐term follow‐up (<a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>). Desmopressin may result in little or no difference in minor adverse events (RR 0.86, 95% CI 0.49 to 1.49) (<a href="./references#CD012059-fig-0012" title="">Analysis 1.9</a>). We rated the quality of evidence as low according to GRADE, downgrading for study limitations and imprecision. </p> </section> <section id="CD012059-sec-0115"> <h6 class="title">4. Treatment withdrawal due to adverse event</h6> <p>We included four studies with 614 men (intervention 367, control 247) for short‐term follow‐up (<a href="./references#CD012059-bbs2-0002" title="CannonA , CarterPG , McConnellAA , AbramsP . Desmopressin in the treatment of nocturnal polyuria in the male. BJU International1999;84(1):20‐4. [PUBMED: 10444118 ] ">Cannon 1999</a>; <a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] ">Rezakhaniha 2011</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>). Desmopressin may result in little or no difference in treatment withdrawal due to adverse events (RR 1.10, 95% CI 0.56 to 2.15) (<a href="./references#CD012059-fig-0013" title="">Analysis 1.10</a>). We rated the quality of evidence as low according to GRADE, downgrading for study limitations and imprecision. </p> <p>We included one study with 115 men (intervention 57, control 58) for intermediate‐term follow‐up (<a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>). Desmopressin may result in little or no difference in treatment withdrawal due to adverse events (RR 3.05, 95% CI 0.13 to 73.39) (<a href="./references#CD012059-fig-0014" title="">Analysis 1.11</a>). We rated the quality of evidence as low according to GRADE, downgrading for study limitations and imprecision. </p> </section> </section> <section id="CD012059-sec-0116"> <h5 class="title">Subgroup analysis</h5> <p>We were able to perform preplanned subgroups for short‐term outcomes only.</p> <section id="CD012059-sec-0117"> <h6 class="title">1. Routes of administration (intranasal, sublingual, or oral)</h6> <section id="CD012059-sec-0118"> <p><b>Number of nocturnal voids</b></p> <p>The mean change in the number of nocturnal voids for intranasal was MD ‐0.20 (95% CI ‐0.34 to ‐0.06), for sublingual was MD ‐0.37 (95% CI ‐0.71 to ‐0.03), and for oral was MD ‐1.14 (95% CI ‐1.41 to ‐0.86). The test for interaction was significant (P &lt; 0.001, I<sup>2</sup> = 94.4%) (<a href="./references#CD012059-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD012059-sec-0119"> <p><b>Major adverse events</b></p> <p>The test for interaction was non‐significant for major adverse events (sublingual: RR 2.53, 95% CI 0.73 to 8.73; oral: RR 0.25, 95% CI 0.03 to 2.37) (P = 0.08, I<sup>2</sup> = 68.0%) (<a href="./references#CD012059-fig-0006" title="">Analysis 1.3</a>). </p> </section> </section> <section id="CD012059-sec-0120"> <h6 class="title">2. Desmopressin dose (very low, low, or high dose)</h6> <section id="CD012059-sec-0121"> <p><b>Number of nocturnal voids</b></p> <p>The mean change in the number of nocturnal voids for the very low dose was MD ‐0.20 (95% CI ‐0.34 to ‐0.06), for low dose was MD ‐0.33 (95% CI ‐0.72 to 0.06), and for high dose was MD ‐1.03 (95% CI ‐1.41 to ‐0.66). The test for interaction was significant (P &lt; 0.001, I<sup>2</sup> = 88.1%) (<a href="./references#CD012059-fig-0015" title="">Analysis 1.12</a>). </p> </section> <section id="CD012059-sec-0122"> <p><b>Major adverse events</b></p> <p>The test for interaction was non‐significant for major adverse events (low dose: RR 2.53, 95% CI 0.73 to 8.73; high dose: RR 0.25, 95% CI 0.03 to 2.37) (P = 0.08, I<sup>2</sup> = 68.0%) (<a href="./references#CD012059-fig-0006" title="">Analysis 1.3</a>). </p> </section> </section> <section id="CD012059-sec-0123"> <h6 class="title">3. Presence of nocturnal polyuria (with or without)</h6> <p>Two studies defined men with nocturia and nocturnal polyuria as inclusion criteria (<a href="https://archie.cochrane.org/sections/documents/view?version=z1709012329593573951893170696034%26format=REVMAN#STD-Cannon-1999" target="_blank">Cannon 1999</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1709012329593573951893170696034%26format=REVMAN#STD-Wang-2011a" target="_blank">Wang 2011a</a>). The remaining studies included men with nocturia without any description of nocturnal polyuria. </p> <section id="CD012059-sec-0124"> <p><b>Number of nocturnal voids</b></p> <p>When comparing men with nocturnal polyuria versus without nocturnal polyuria, we found an MD of ‐1.28 (95% CI ‐1.64 to ‐0.92) with nocturnal polyuria versus an MD of ‐0.45 (95% CI ‐0.73 to ‐0.17) without nocturnal polyuria. The test for interaction was significant (P &lt; 0.001, I<sup>2</sup> = 92.1%) (<a href="./references#CD012059-fig-0016" title="">Analysis 1.13</a>). </p> </section> <section id="CD012059-sec-0125"> <p><b>Major adverse events</b></p> <p>As eligible studies in this analysis did not include men with nocturia and nocturnal polyuria, we were unable to perform a subgroup analysis. </p> </section> </section> </section> <section id="CD012059-sec-0126"> <h5 class="title">Sensitivity analysis</h5> <section id="CD012059-sec-0127"> <h6 class="title">1. Restricting the analysis by considering risk of bias, excluding studies at 'high risk' or 'unclear risk' </h6> <p>We rated all included studies as at high or unclear risk of bias and were therefore unable to perform a sensitivity analysis. </p> </section> <section id="CD012059-sec-0128"> <h6 class="title">2. Restricting the analysis by considering risk of bias, excluding studies with run‐in periods </h6> <section id="CD012059-sec-0129"> <p><b>Number of nocturnal voids</b></p> <p>We included four studies with 966 men (intervention 665, control 301) for short‐term follow‐up (<a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). The MD for this sensitivity analysis was ‐0.66 (95% CI ‐1.17 to ‐0.14) compared to an MD of ‐0.61 (95% CI ‐0.96 to ‐0.27) for the main analysis (<a href="./references#CD012059-fig-0017" title="">Analysis 1.14</a>). </p> <p>The results of the main and sensitivity analyses were the same for intermediate‐term follow‐up. </p> </section> <section id="CD012059-sec-0130"> <p><b>Major adverse events</b></p> <p>We included one study with 385 men (intervention 243, control 142) for short‐term follow‐up (<a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>). Sensitivity analyses (RR 2.53, 95% CI 0.73 to 8.73) did not alter the treatment effect compared to the main analysis (RR 0.97, 95% CI 0.10 to 9.03) (<a href="./references#CD012059-fig-0018" title="">Analysis 1.15</a>). </p> </section> </section> <section id="CD012059-sec-0131"> <h6 class="title">3. Restricting the analysis by considering clinically recommended dosage of desmopressin, excluding lower dose levels </h6> <section id="CD012059-sec-0132"> <p><b>Number of nocturnal voids</b></p> <p>We included six studies with 1586 men (intervention 964, control 622) for short‐term follow‐up (<a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a>; <a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a>; <a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>; <a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a>). The MD for this sensitivity analysis was ‐0.76 (95% CI ‐1.15 to ‐0.38) compared to an MD of ‐0.61 (95% CI ‐0.96 to ‐0.27) for the main analysis (<a href="./references#CD012059-fig-0019" title="">Analysis 1.16</a>). </p> <p>The results of the main and sensitivity analyses were the same for intermediate‐term follow‐up. </p> </section> <section id="CD012059-sec-0133"> <p><b>Major adverse events</b></p> <p>We included two studies with 417 men (intervention 210, control 207) for short‐term follow‐up (<a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a>; <a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a>). Sensitivity analyses (RR 0.98, 95% CI 0.10 to 9.71) did not alter the treatment effect substantially compared to the main analysis (RR 0.97, 95% CI 0.10 to 9.03) (<a href="./references#CD012059-fig-0020" title="">Analysis 1.17</a>). </p> </section> </section> </section> </section> <section id="CD012059-sec-0134"> <h4 class="title">Desmopressin versus behaviour modification</h4> <p>We found one study with 60 men (intervention 30, control 30) comparing desmopressin versus behaviour modification for short‐term follow‐up (<a href="./references#CD012059-bbs2-0011" title="WangW , ChenS . Low dose oral desmopressin in treatment of nocturia in elderly men. Urology2012;80(3 Suppl):S117. [DOI: 10.1016/S0090‐4295(12)00880‐1] ">Wang 2012</a>; <a href="./full#CD012059-tbl-0003">summary of findings Table 3</a>). </p> <section id="CD012059-sec-0135"> <h5 class="title">Primary outcomes</h5> <section id="CD012059-sec-0136"> <h6 class="title">1. Number of nocturnal voids</h6> <p>The study did not report number of nocturnal voids.</p> </section> <section id="CD012059-sec-0137"> <h6 class="title">2. Quality of life</h6> <p>The study did not report quality of life.</p> </section> <section id="CD012059-sec-0138"> <h6 class="title">3. Major adverse events</h6> <p>The study did not report major adverse events.</p> </section> </section> <section id="CD012059-sec-0139"> <h5 class="title">Secondary outcomes</h5> <section id="CD012059-sec-0140"> <h6 class="title">1. Duration of first sleep episode</h6> <p>Desmopressin may result in a small, possibly unimportant effect on duration of first sleep episode (MD 90.00 minutes, 95% CI 1.95 to 178.05) (<a href="./references#CD012059-fig-0021" title="">Analysis 2.1</a>). We rated the quality of evidence as low according to GRADE, downgrading for study limitations and imprecision. </p> </section> <section id="CD012059-sec-0141"> <h6 class="title">2. Time to first void</h6> <p>The study did not report time to first void.</p> </section> <section id="CD012059-sec-0142"> <h6 class="title">3. Minor adverse events</h6> <p>The study did not report minor adverse events.</p> </section> <section id="CD012059-sec-0143"> <h6 class="title">4. Treatment withdrawal due to adverse event</h6> <p>The study did not report treatment withdrawal due to adverse event.</p> </section> </section> <section id="CD012059-sec-0144"> <h5 class="title">Subgroup and sensitivity analysis</h5> <p>We were unable to perform any of the planned secondary analyses due to a paucity of included studies or lack of relevant data in the included studies. </p> </section> </section> <section id="CD012059-sec-0145"> <h4 class="title">Desmopressin versus alpha‐blocker</h4> <p>We included one study with 31 men (intervention 15, control 16) comparing desmopressin versus alpha‐blocker for all review outcomes in short‐term follow‐up (<a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a>; <a href="./full#CD012059-tbl-0004">summary of findings Table 4</a>) There were no studies with intermediate‐ or long‐term follow‐up. </p> <section id="CD012059-sec-0146"> <h5 class="title">Primary outcomes</h5> <section id="CD012059-sec-0147"> <h6 class="title">1. Number of nocturnal voids</h6> <p>Desmopressin likely results in little or no difference in the number of nocturnal voids (MD 0.30, 95% CI ‐0.20 to 0.80) (<a href="./references#CD012059-fig-0022" title="">Analysis 3.1</a>). We rated the quality of evidence as moderate according to GRADE, downgrading for study limitations. </p> </section> <section id="CD012059-sec-0148"> <h6 class="title">2. Quality of life</h6> <p>Desmopressin likely results in little or no difference in quality of life (MD 0.00, 95% CI ‐0.35 to 0.35) (<a href="./references#CD012059-fig-0023" title="">Analysis 3.2</a>). We rated the quality of evidence as moderate according to GRADE, downgrading for study limitations. </p> </section> <section id="CD012059-sec-0149"> <h6 class="title">3. Major adverse events</h6> <p>No major adverse events were reported in either study group.</p> </section> </section> <section id="CD012059-sec-0150"> <h5 class="title">Secondary outcomes</h5> <section id="CD012059-sec-0151"> <h6 class="title">1. Duration of first sleep episode</h6> <p>The study did not report duration of first sleep episode.</p> </section> <section id="CD012059-sec-0152"> <h6 class="title">2. Time to first void</h6> <p>The study did not report time to first void.</p> </section> <section id="CD012059-sec-0153"> <h6 class="title">3. Minor adverse events</h6> <p>We are uncertain about the effect on minor adverse events (RR 1.07, 95% CI 0.07 to 15.57) (<a href="./references#CD012059-fig-0025" title="">Analysis 3.4</a>). We rated the quality of evidence as very low according to GRADE, downgrading for study limitations and twice for imprecision. </p> </section> <section id="CD012059-sec-0154"> <h6 class="title">4. Treatment withdrawal due to adverse event</h6> <p>No treatment withdrawals due to adverse events were reported in either study group.</p> </section> </section> <section id="CD012059-sec-0155"> <h5 class="title">Subgroup and sensitivity analysis</h5> <p>We were unable to perform any of the planned secondary analyses due to a paucity of included studies or lack of relevant data in the included studies. </p> </section> </section> <section id="CD012059-sec-0156"> <h4 class="title">Desmopressin plus alpha‐blocker versus alpha‐blocker</h4> <p>We included three studies comparing desmopressin plus alpha‐blocker versus alpha‐blocker with short‐term follow‐up (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>; <a href="./full#CD012059-tbl-0005">summary of findings Table 5</a>). There were no studies with intermediate‐ or long‐term follow‐up. </p> <section id="CD012059-sec-0157"> <h5 class="title">Primary outcomes</h5> <section id="CD012059-sec-0158"> <h6 class="title">1. Number of nocturnal voids</h6> <p>We included three studies with 341 men (intervention 176, control 165) (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>). Desmopressin combined with an alpha‐blocker likely results in a small, possibly unimportant effect on the number of nocturnal voids (MD ‐0.47, 95% CI ‐0.73 to ‐0.21) (<a href="./references#CD012059-fig-0027" title="">Analysis 4.1</a>). We rated the quality of evidence as moderate according to GRADE, downgrading for study limitations. </p> </section> <section id="CD012059-sec-0159"> <h6 class="title">2. Quality of life</h6> <p>We included three studies with 341 men (intervention 176, control 165) (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>). Desmopressin combined with an alpha‐blocker likely results in a small, possibly unimportant effect on quality of life (MD ‐0.29, 95% CI ‐0.51 to ‐0.07) (<a href="./references#CD012059-fig-0029" title="">Analysis 4.3</a>). We rated the quality of evidence as moderate according to GRADE, downgrading for study limitations. </p> </section> <section id="CD012059-sec-0160"> <h6 class="title">3. Major adverse events</h6> <p>We included three studies with 402 men (intervention 202, control 200) (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>). Desmopressin combined with an alpha‐blocker may result in little to no difference in major adverse events (RR 0.30, 95% CI 0.01 to 7.32) (<a href="./references#CD012059-fig-0031" title="">Analysis 4.5</a>). There was only one adverse event in the control group in one study (<a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>). We rated the quality of evidence as low according to GRADE, downgrading for study limitations and imprecision. </p> </section> </section> <section id="CD012059-sec-0161"> <h5 class="title">Secondary outcomes</h5> <section id="CD012059-sec-0162"> <h6 class="title">1. Duration of first sleep episode</h6> <p>No study reported duration of first sleep episode.</p> </section> <section id="CD012059-sec-0163"> <h6 class="title">2. Time to first void</h6> <p>No study reported time to first void.</p> </section> <section id="CD012059-sec-0164"> <h6 class="title">3. Minor adverse events</h6> <p>We included three studies with 402 men (intervention 202, control 200) (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>). We are uncertain about the effect on minor adverse events (RR 1.60, 95% CI 0.15 to 16.82) (<a href="./references#CD012059-fig-0033" title="">Analysis 4.7</a>). We rated the quality of evidence as very low according to GRADE, downgrading for study limitations and twice for imprecision. </p> </section> <section id="CD012059-sec-0165"> <h6 class="title">4. Treatment withdrawal due to adverse event</h6> <p>We included three studies with 402 men (intervention 202, control 200) (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>; <a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a>; <a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a>). Desmopressin combined with an alpha‐blocker may result in little to no difference in treatment withdrawal due to adverse events (RR 2.84, 95% CI 0.46 to 17.66) (<a href="./references#CD012059-fig-0034" title="">Analysis 4.8</a>). We rated the quality of evidence as low according to GRADE, downgrading for study limitations and imprecision. </p> </section> </section> <section id="CD012059-sec-0166"> <h5 class="title">Subgroup analysis</h5> <section id="CD012059-sec-0167"> <h6 class="title">1. Desmopressin route of administration and dose (intranasal/very low, sublingual/low, or oral/high) </h6> <section id="CD012059-sec-0168"> <p><b>Number of nocturnal voids</b></p> <p>The mean change in the number of nocturnal voids for sublingual/low dose was MD ‐0.66 (95% CI ‐0.90 to ‐0.42) and for oral/high dose was MD ‐0.31 (95% CI ‐0.60 to ‐0.02). The test for interaction was non‐significant (P = 0.06, I<sup>2</sup> = 70.8%) (<a href="./references#CD012059-fig-0027" title="">Analysis 4.1</a>). </p> </section> <section id="CD012059-sec-0169"> <p><b>Quality of life</b></p> <p>The mean change in quality of life score for sublingual/low dose was MD ‐0.23 (95% CI ‐0.49 to 0.03) and for oral/high dose was MD ‐0.44 (95% CI ‐0.85 to ‐0.03). The test for interaction was non‐significant (P = 0.41, I<sup>2</sup> = 0.0%) (<a href="./references#CD012059-fig-0029" title="">Analysis 4.3</a>). </p> </section> <section id="CD012059-sec-0170"> <p><b>Major adverse events</b></p> <p>We were unable to estimate the subgroup difference due to no events in the sublingual/low‐dose group (<a href="./references#CD012059-fig-0031" title="">Analysis 4.5</a>). </p> </section> </section> <section id="CD012059-sec-0171"> <h6 class="title">2. Presence of nocturnal polyuria (with or without)</h6> <section id="CD012059-sec-0172"> <p><b>Number of nocturnal voids</b></p> <p>When comparing men with nocturnal polyuria versus without nocturnal polyuria, we found an MD of ‐0.30 (95% CI ‐0.74 to 0.14) with nocturnal polyuria versus an MD of ‐0.52 (95% CI ‐0.86 to ‐0.18) without nocturnal polyuria. The test for interaction was non‐significant (P = 0.44, I<sup>2</sup> = 0.0%) (<a href="./references#CD012059-fig-0028" title="">Analysis 4.2</a>). </p> </section> <section id="CD012059-sec-0173"> <p><b>Quality of life</b></p> <p>We found an MD of ‐0.20 (95% CI ‐0.84 to 0.44) for men with nocturnal polyuria versus an MD of ‐0.34 (95% CI ‐0.67 to ‐0.01) for men without nocturnal polyuria. The test for interaction was non‐significant (P = 0.71, I<sup>2</sup> = 0.0%) (<a href="./references#CD012059-fig-0030" title="">Analysis 4.4</a>). </p> </section> <section id="CD012059-sec-0174"> <p><b>Major adverse events</b></p> <p>We were unable to estimate the subgroup difference due to no events in men with nocturia (<a href="./references#CD012059-fig-0032" title="">Analysis 4.6</a>). </p> </section> </section> </section> <section id="CD012059-sec-0175"> <h5 class="title">Sensitivity analysis</h5> <p>The results of the main and sensitivity analyses were the same.</p> </section> </section> <section id="CD012059-sec-0176"> <h4 class="title">Desmopressin plus alpha‐blocker versus alpha‐blocker plus anticholinergic</h4> <p>We included one study with short‐term follow‐up in this comparison (<a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a>; <a href="./full#CD012059-tbl-0006">summary of findings Table 6</a>). There were no studies with intermediate‐ or long‐term follow‐up. </p> <section id="CD012059-sec-0177"> <h5 class="title">Primary outcomes</h5> <section id="CD012059-sec-0178"> <h6 class="title">1. Number of nocturnal voids</h6> <p>We included 405 men (intervention 196, control 209). Desmopressin combined with alpha‐blocker likely results in little or no difference in the number of nocturnal voids (MD ‐0.43, 95% CI ‐0.97 to 0.11) (<a href="./references#CD012059-fig-0035" title="">Analysis 5.1</a>). We rated the quality of evidence as moderate according to GRADE, downgrading for study limitations. </p> </section> <section id="CD012059-sec-0179"> <h6 class="title">2. Quality of life</h6> <p>The study did not report quality of life.</p> </section> <section id="CD012059-sec-0180"> <h6 class="title">3. Major adverse events</h6> <p>We included 427 men (intervention 205, control 222). No major adverse events were reported in either study group. </p> </section> </section> <section id="CD012059-sec-0181"> <h5 class="title">Secondary outcomes</h5> <section id="CD012059-sec-0182"> <h6 class="title">1. Duration of first sleep episode</h6> <p>The study did not report duration of first sleep episode.</p> </section> <section id="CD012059-sec-0183"> <h6 class="title">2. Time to first void</h6> <p>The study did not report time to first void.</p> </section> <section id="CD012059-sec-0184"> <h6 class="title">3. Minor adverse events</h6> <p>We included 427 men (intervention 205, control 222). Desmopressin combined with alpha‐blocker may result in a small, possibly unimportant effect on minor adverse events (RR 0.22, 95% CI 0.05 to 0.98) (<a href="./references#CD012059-fig-0037" title="">Analysis 5.3</a>). We rated the quality of evidence as low according to GRADE, downgrading for study limitations and imprecision. </p> </section> <section id="CD012059-sec-0185"> <h6 class="title">4. Treatment withdrawal due to adverse event</h6> <p>We included 427 men (intervention 205, control 222). Desmopressin combined with alpha‐blocker may result in a small, possibly unimportant effect on treatment withdrawal due to adverse events (RR 0.22, 95% CI 0.05 to 0.98) (<a href="./references#CD012059-fig-0038" title="">Analysis 5.4</a>). We rated the quality of evidence as low according to GRADE, downgrading for study limitations and imprecision. </p> </section> </section> <section id="CD012059-sec-0186"> <h5 class="title">Subgroup and sensitivity analysis</h5> <p>We were unable to perform any of the planned secondary analyses due to a paucity of included studies or lack of relevant data in the included studies. </p> </section> </section> <section id="CD012059-sec-0187"> <h4 class="title">Desmopressin versus surgery</h4> <p>We found no trials comparing desmopressin versus surgery.</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012059-sec-0188" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012059-sec-0188"></div> <section id="CD012059-sec-0189"> <h3 class="title" id="CD012059-sec-0189">Summary of main results</h3> <p>We included 14 unique studies with 2966 male participants with nocturia across five comparisons. We included all comparisons with short‐term follow‐up and one comparison (desmopressin versus placebo) with intermediate‐term follow‐up. The mean age of the male participants ranged from 57 to 74 years. </p> <section id="CD012059-sec-0190"> <h4 class="title">Desmopressin versus placebo</h4> <p>Based on short‐term follow‐up, desmopressin may reduce the number of nocturnal voids, but this may not represent a clinically important reduction to patients. We are uncertain about the effect of desmopressin on major adverse events. </p> <p>For intermediate‐term follow‐up, desmopressin may reduce number of nocturnal voids in comparison to placebo in an appreciable number of men. Desmopressin may result in little or no difference in major adverse events. </p> <p>None of the studies reported quality of life.</p> <p>Subgroup analyses suggest a larger effect with oral, higher‐dose formulations of desmopressin and in men with documented nocturnal polyuria. Sensitivity analyses based on risk of bias, run‐in periods, and clinical dosage of desmopressin did not alter the treatment effect substantially. </p> </section> <section id="CD012059-sec-0191"> <h4 class="title">Desmopressin versus behaviour modification</h4> <p>We found no evidence on primary outcomes for the comparison of desmopressin versus behaviour modification. </p> </section> <section id="CD012059-sec-0192"> <h4 class="title">Desmopressin versus alpha‐blocker</h4> <p>Based on short‐term follow‐up, desmopressin likely has a similar effect to alpha‐blocker on the number of nocturnal voids and quality of life. No major adverse events were reported in either study group. </p> </section> <section id="CD012059-sec-0193"> <h4 class="title">Desmopressin plus alpha‐blocker versus alpha‐blocker</h4> <p>Based on short‐term follow‐up, combination therapy likely results in a small, possibly unimportant effect compared with desmopressin alone on the number of nocturnal voids and quality of life. Combination therapy was not associated with a meaningful impact on major adverse events. </p> </section> <section id="CD012059-sec-0194"> <h4 class="title">Desmopressin plus alpha‐blocker versus alpha‐blocker plus anticholinergic</h4> <p>Based on short‐term follow‐up, desmopressin plus alpha‐blocker likely results in little or no difference compared with an alpha‐blocker plus anticholinergic in the number of nocturnal voids. We found no evidence on quality of life. No major adverse events were reported in either study group. </p> </section> <section id="CD012059-sec-0195"> <h4 class="title">Desmopressin versus surgery</h4> <p>We found no studies comparing desmopressin to surgical interventions.</p> </section> </section> <section id="CD012059-sec-0196"> <h3 class="title" id="CD012059-sec-0196">Overall completeness and applicability of evidence</h3> <p> <ul id="CD012059-list-0023"> <li> <p>The focus of this systematic review was male participants with nocturia irrespective of aetiology but excluding men with known metabolic disorders potentially associated with a secondary nocturnal diuresis, such as Cushing disease. We included men with and without nocturnal polyuria, since desmopressin has been used in both patient populations. </p> </li> <li> <p>This review included three different formulations of desmopressin with different bioavailability. While we labelled the dosage as high, low, and very low in this review, actual bioavailability may be different. </p> </li> <li> <p>The existing body of evidence was largely limited to short‐term outcomes, with 13 of 14 studies reporting outcomes of three months' duration or less. Given the usually chronic nature of men's nocturia complaints, such short‐term outcomes appear to be insufficient to provide assurance of long‐term effectiveness and safety. </p> </li> <li> <p>Desmopressin is known to lower serum sodium levels. We made a conscious decision not to include serum sodium levels as an outcome of this review given that their levels per se are not patient important. Instead, we focused on both major and minor adverse events, expecting that clinically important serum sodium level reductions would have been reflected in the event rates for these outcomes. The findings of this review did not suggest increased rates for either outcomes, although the quality of evidence was only low or very low. However, participants in clinical trials are commonly monitored more closely than in routine clinical practice, thereby potentially reducing the risk of adverse events and limiting the applicability of our findings. In addition, as previously mentioned, the time‐horizon of most included studies was short, thereby negating the opportunity for us to document any long‐term effects of desmopressin on serum sodium levels. Large observational studies may therefore provide additional insight into the 'real‐life' safety profile of this drug when used longer term. </p> </li> <li> <p>We identified trials that appeared to be eligible for inclusion but did not provide data in such a way as to allow analyses, for example results reporting by gender group. Our efforts to obtain additional information from the manufacturers and trial sponsors were largely unsuccessful. This raises concerns about selective reporting and potential publication bias, although we found insufficient indication to downgrade the quality of evidence for publication bias. </p> </li> <li> <p>Given that one‐third of trials had active run‐in periods, study findings may have been biased in favour of the intervention, since people with adverse events or limited compliance may have been excluded up‐front. </p> </li> <li> <p>We performed subgroup analyses based on the presence or absence of nocturnal polyuria. Four trials included men with documented nocturnal polyuria, defined as more than 30% or one‐third of a person's 24‐hour urine output excreted during their sleeping time. However, the other trials did not describe whether the men had nocturnal polyuria or not. Given that this analysis did not exactly match our intended analysis, we are less confident in its findings. These analyses may also have been underpowered to detect a difference. </p> </li> <li> <p>There were small differences in the pooled effect estimates among subgroups, which may represent true differences or spurious findings due to prognostic imbalances in the absence of stratified randomisation. </p> </li> </ul> </p> </section> <section id="CD012059-sec-0197"> <h3 class="title" id="CD012059-sec-0197">Quality of the evidence</h3> <p>We rated the quality of evidence as low or moderate for most outcomes and comparisons. Our confidence in the estimates of effect were lowered for the following reasons. </p> <p> <ul id="CD012059-list-0024"> <li> <p>Study limitation: issues surrounding allocation concealment and blinding.</p> </li> <li> <p>Inconsistency: high I<sup>2</sup> values, which we were unable to explain through secondary analyses. </p> </li> <li> <p>Imprecision: few events resulting in wide CIs.</p> </li> </ul> </p> </section> <section id="CD012059-sec-0198"> <h3 class="title" id="CD012059-sec-0198">Potential biases in the review process</h3> <p> <ul id="CD012059-list-0025"> <li> <p>In order to reduce the potential for publication bias, we followed a published protocol (<a href="./references#CD012059-bbs2-0058" title="HanJ , SukumarS , BakkerCJ , EbellMH , DahmP . Desmopressin for treating nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Cochrane Database of Systematic Reviews2016, Issue 1. [DOI: 10.1002/14651858.CD012059] ">Han 2016</a>), and performed a comprehensive and updated literature search without publication or language restriction. In addition, we searched trial registries for unpublished, planned, or ongoing studies. We found a few abstract proceedings of the annual meetings of the American Urological Association, European Association of Urology, International Continence Society, and the British Association of Urological Surgeons from 2012 to 2017 and one ongoing trial. Should any results of such studies become available, we will include them in updates of this review. </p> </li> <li> <p>We contacted study authors on several occasions, who provided feedback to some of our queries. However, we received additional information from only two out of six study authors. This may represent a source of bias with potential under‐reporting of the true treatment burden. </p> </li> <li> <p>We included only randomised controlled trials in this review, which were all relatively small and had a short time‐horizon. To understand infrequent and long‐term adverse events better, additional non‐randomised studies are likely necessary but were outside the scope of this review. </p> </li> </ul> </p> </section> <section id="CD012059-sec-0199"> <h3 class="title" id="CD012059-sec-0199">Agreements and disagreements with other studies or reviews</h3> <p>A systematic review assessing the efficacy and safety of desmopressin for nocturia in adults was published in 2014 (<a href="./references#CD012059-bbs2-0048" title="EbellMH , RadkeT , GardnerJ . A systematic review of the efficacy and safety of desmopressin for nocturia in adults. Journal of Urology2014;192(3):829‐35. ">Ebell 2014</a>). The review included 10 studies with 2191 participants, of which several studies included a significant portion of women. We excluded studies with only women from our review, as we focused on the use of desmopressin to treat nocturia in men. One study comparing desmopressin in addition to alpha‐blocker therapy versus alpha‐blocker therapy alone was published after the systematic review by Ebell and colleagues (<a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a>). Similar to our review, <a href="./references#CD012059-bbs2-0048" title="EbellMH , RadkeT , GardnerJ . A systematic review of the efficacy and safety of desmopressin for nocturia in adults. Journal of Urology2014;192(3):829‐35. ">Ebell 2014</a> found a small improvement in nocturia mainly based on a small decrease in the number of nocturnal voids and increase in duration of first sleep episode (<a href="./references#CD012059-bbs2-0048" title="EbellMH , RadkeT , GardnerJ . A systematic review of the efficacy and safety of desmopressin for nocturia in adults. Journal of Urology2014;192(3):829‐35. ">Ebell 2014</a>). The authors viewed desmopressin as generally safe with an overall favourable adverse effect profile and very rare major adverse events. In congruence with our review, their results were limited to the short term, and they acknowledged the need for additional, well‐designed studies of longer duration. These reviews did not use GRADE or assess the quality of evidence on a per‐outcome basis. </p> <p>Another review discussing the medical treatment of nocturia in men with LUTS found that desmopressin was more effective than placebo in decreasing nocturnal voiding frequency and increasing duration of undisturbed sleep (<a href="./references#CD012059-bbs2-0075" title="SakalisVI , KaravitakisM , BedretdinovaD , BachT , BoschJLHR , GacciM , et al. Medical treatment of nocturia in men with lower urinary tract symptoms: systematic review by the European Association of Urology Guidelines Panel for Male Lower Urinary Tract Symptoms. European Urology 2017 Jun 27 [Epub ahead of print]. [DOI: 10.1016/j.eururo.2017.06.010] ">Sakalis 2017</a>). However, of the included studies, three trials had mixed populations of men and women. Given the review's clearly defined focus on men and the unique pathophysiology of men, we believe these studies introduced meaningful heterogeneity and should have been excluded. Furthermore, another included study compared furosemide (a diuretic) with desmopressin to placebo, and the contribution of each drug could not be isolated. This review provided no quality of evidence ratings and did not use an explicit CID (<a href="./references#CD012059-bbs2-0066" title="JungJH , HanJL , DahmP . Re: Vasileios I. Sakalis, Markos Karavitakis, Dina Bedretdinova, et al. Medical treatment of nocturia in men with lower urinary tract symptoms: systematic review by the European Association of Urology Guidelines Panel for Male Lower Urinary Tract Symptoms. European Urology2017;72:757–69. ">Jung 2017</a>). They found an MD of ‐0.87 (95% CI ‐1.15 to ‐0.60) comparing desmopressin to placebo; the proposed CID is a reduction of at least one episode per night (<a href="./references#CD012059-bbs2-0067" title="KraderCG . Antimuscarinic decreases nocturnal urgency episodes. urologytimes.modernmedicine.com/urology‐times/news/clinical/clinical‐pharmacology/antimuscarinic‐decreases‐nocturnal‐urgency‐episode (accessed 5 September 2017). ">Krader 2012</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012059-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram." data-id="CD012059-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/full#CD012059-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD012059-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/full#CD012059-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies." data-id="CD012059-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/full#CD012059-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Desmopressin versus placebo, Outcome 1 Number of nocturnal voids (short term) (subgroup route)." data-id="CD012059-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Desmopressin versus placebo, Outcome 1 Number of nocturnal voids (short term) (subgroup route). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Desmopressin versus placebo, Outcome 2 Number of nocturnal voids (intermediate term)." data-id="CD012059-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Desmopressin versus placebo, Outcome 2 Number of nocturnal voids (intermediate term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Desmopressin versus placebo, Outcome 3 Major adverse events (short term) (subgroup route and dose)." data-id="CD012059-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Desmopressin versus placebo, Outcome 3 Major adverse events (short term) (subgroup route and dose). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Desmopressin versus placebo, Outcome 4 Major adverse events (intermediate term)." data-id="CD012059-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Desmopressin versus placebo, Outcome 4 Major adverse events (intermediate term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Desmopressin versus placebo, Outcome 5 Duration of first sleep episode (short term)." data-id="CD012059-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Desmopressin versus placebo, Outcome 5 Duration of first sleep episode (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Desmopressin versus placebo, Outcome 6 Duration of first sleep episode (intermediate term)." data-id="CD012059-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Desmopressin versus placebo, Outcome 6 Duration of first sleep episode (intermediate term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Desmopressin versus placebo, Outcome 7 Time to first void (short term) [minutes]." data-id="CD012059-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Desmopressin versus placebo, Outcome 7 Time to first void (short term) [minutes]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Desmopressin versus placebo, Outcome 8 Minor adverse events (short term)." data-id="CD012059-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Desmopressin versus placebo, Outcome 8 Minor adverse events (short term).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Desmopressin versus placebo, Outcome 9 Minor adverse events (intermediate term)." data-id="CD012059-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Desmopressin versus placebo, Outcome 9 Minor adverse events (intermediate term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Desmopressin versus placebo, Outcome 10 Treatment withdrawal due to adverse event (short term)." data-id="CD012059-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Desmopressin versus placebo, Outcome 10 Treatment withdrawal due to adverse event (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Desmopressin versus placebo, Outcome 11 Treatment withdrawal due to adverse event (intermediate term)." data-id="CD012059-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Desmopressin versus placebo, Outcome 11 Treatment withdrawal due to adverse event (intermediate term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Desmopressin versus placebo, Outcome 12 Number of nocturnal voids (short term) (subgroup dose)." data-id="CD012059-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Desmopressin versus placebo, Outcome 12 Number of nocturnal voids (short term) (subgroup dose). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Desmopressin versus placebo, Outcome 13 Number of nocturnal voids (short term) (subgroup nocturnal polyuria)." data-id="CD012059-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Desmopressin versus placebo, Outcome 13 Number of nocturnal voids (short term) (subgroup nocturnal polyuria). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Desmopressin versus placebo, Outcome 14 Number of nocturnal voids (short term) (sensitivity run‐in period)." data-id="CD012059-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Desmopressin versus placebo, Outcome 14 Number of nocturnal voids (short term) (sensitivity run‐in period). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Desmopressin versus placebo, Outcome 15 Major adverse events (short term) (sensitivity run‐in period)." data-id="CD012059-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Desmopressin versus placebo, Outcome 15 Major adverse events (short term) (sensitivity run‐in period). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Desmopressin versus placebo, Outcome 16 Number of nocturnal voids (short term) (sensitivity clinical dosage)." data-id="CD012059-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Desmopressin versus placebo, Outcome 16 Number of nocturnal voids (short term) (sensitivity clinical dosage). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Desmopressin versus placebo, Outcome 17 Major adverse events (short term) (sensitivity clinical dosage)." data-id="CD012059-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Desmopressin versus placebo, Outcome 17 Major adverse events (short term) (sensitivity clinical dosage). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Desmopressin versus behaviour modification, Outcome 1 Duration of first sleep episode (short term)." data-id="CD012059-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Desmopressin versus behaviour modification, Outcome 1 Duration of first sleep episode (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Desmopressin versus alpha‐blocker, Outcome 1 Number of nocturnal voids (short term)." data-id="CD012059-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Desmopressin versus alpha‐blocker, Outcome 1 Number of nocturnal voids (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Desmopressin versus alpha‐blocker, Outcome 2 Quality of life (short term)." data-id="CD012059-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Desmopressin versus alpha‐blocker, Outcome 2 Quality of life (short term).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Desmopressin versus alpha‐blocker, Outcome 3 Major adverse events (short term)." data-id="CD012059-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Desmopressin versus alpha‐blocker, Outcome 3 Major adverse events (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Desmopressin versus alpha‐blocker, Outcome 4 Minor adverse events (short term)." data-id="CD012059-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Desmopressin versus alpha‐blocker, Outcome 4 Minor adverse events (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Desmopressin versus alpha‐blocker, Outcome 5 Treatment withdrawal due to adverse event (short term)." data-id="CD012059-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Desmopressin versus alpha‐blocker, Outcome 5 Treatment withdrawal due to adverse event (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 1 Number of nocturnal voids (short term) (subgroup route and dose)." data-id="CD012059-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 1 Number of nocturnal voids (short term) (subgroup route and dose). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 2 Number of nocturnal voids (short term) (subgroup nocturnal polyuria)." data-id="CD012059-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 2 Number of nocturnal voids (short term) (subgroup nocturnal polyuria). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 3 Quality of life (short term) (subgroup route and dose)." data-id="CD012059-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 3 Quality of life (short term) (subgroup route and dose). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 4 Quality of life (short term) (subgroup nocturnal polyuria)." data-id="CD012059-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 4 Quality of life (short term) (subgroup nocturnal polyuria). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 5 Major adverse events (short term) (subgroup route and dose)." data-id="CD012059-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 5 Major adverse events (short term) (subgroup route and dose). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 6 Major adverse events (short term) (subgroup nocturnal polyuria)." data-id="CD012059-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 6 Major adverse events (short term) (subgroup nocturnal polyuria). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 7 Minor adverse events (short term)." data-id="CD012059-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 7 Minor adverse events (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 8 Treatment withdrawal due to adverse event (short term)." data-id="CD012059-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 8 Treatment withdrawal due to adverse event (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Desmopressin plus alpha‐blocker versus alpha‐blocker plus anticholinergic, Outcome 1 Number of nocturnal voids (short term)." data-id="CD012059-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Desmopressin plus alpha‐blocker versus alpha‐blocker plus anticholinergic, Outcome 1 Number of nocturnal voids (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Desmopressin plus alpha‐blocker versus alpha‐blocker plus anticholinergic, Outcome 2 Major adverse events (short term)." data-id="CD012059-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Desmopressin plus alpha‐blocker versus alpha‐blocker plus anticholinergic, Outcome 2 Major adverse events (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Desmopressin plus alpha‐blocker versus alpha‐blocker plus anticholinergic, Outcome 3 Minor adverse events (short term)." data-id="CD012059-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Desmopressin plus alpha‐blocker versus alpha‐blocker plus anticholinergic, Outcome 3 Minor adverse events (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012059-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/urn:x-wiley:14651858:media:CD012059:CD012059-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_t/tCD012059-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Desmopressin plus alpha‐blocker versus alpha‐blocker plus anticholinergic, Outcome 4 Treatment withdrawal due to adverse event (short term)." data-id="CD012059-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Desmopressin plus alpha‐blocker versus alpha‐blocker plus anticholinergic, Outcome 4 Treatment withdrawal due to adverse event (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/media/CDSR/CD012059/image_n/nCD012059-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012059-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Desmopressin versus placebo for men with nocturia (short term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> men with nocturia </p> <p><b>Setting:</b> likely outpatient </p> <p><b>Intervention:</b> desmopressin </p> <p><b>Control:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk difference with desmopressin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of nocturnal voids</b><br/> assessed with: voiding diary<br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1982<br/> (6 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean number of nocturnal voids ranged from 1.9 to 4.57.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.61 lower<br/> (0.96 lower to 0.27 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major adverse events</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>536<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/> (0.10 to 9.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 fewer per 1000<br/> (26 fewer to 233 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of first sleep episode</b><br/> assessed with: voiding diary<br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>652<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean duration of first sleep episode ranged from 26.21 to 174 minutes.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 54.61 minutes higher<br/> (13.97 higher to 95.25 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first void</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>383<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean time to first void was 72.9 minutes.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 40.8 minutes higher<br/> (17.07 higher to 64.53 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Minor adverse event</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>594<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.87<br/> (0.67 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 fewer per 1000<br/> (33 more to 85 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawal due to adverse event</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>614<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.10<br/> (0.56 to 2.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 more per 1000<br/> (21 fewer to 56 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for study limitations: unclear or high risk of bias for one or more domains in at least 50% of the studies.<br/> <sup>2</sup>Downgraded by one level for inconsistency: substantial heterogeneity among studies.<br/> <sup>3</sup>Downgraded by one level for imprecision: confidence interval was wide or crossed assumed threshold of clinically important difference (or both). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Desmopressin versus placebo for men with nocturia (short term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/full#CD012059-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012059-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Desmopressin versus placebo for men with nocturia (intermediate term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> men with nocturia </p> <p><b>Setting:</b> likely outpatient </p> <p><b>Intervention:</b> desmopressin </p> <p><b>Control:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk difference with desmopressin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of nocturnal voids</b><br/> assessed with: voiding diary<br/> follow‐up: range 3 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>115<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of nocturnal voids was 4.14 voids.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.85 voids fewer<br/> (1.17 fewer to 0.53 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major adverse events</b><br/> follow‐up: range 3 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>115<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.05<br/> (0.13 to 73.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of first sleep episode</b><br/> assessed with: voiding diary<br/> follow‐up: range 3 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>115<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean duration of first sleep episode was 101.6 minutes.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 18.4 minutes higher<br/> (11.6 higher to 25.2 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first void</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Minor adverse events</b><br/> follow‐up: range 3 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>115<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/> (0.49 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>328 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 fewer per 1000<br/> (167 fewer to 161 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawal due to adverse event</b><br/> follow‐up: range 3 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>115<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.05<br/> (0.13 to 73.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for study limitations: unclear risk of bias for one or more domains in the included study.<br/> <sup>2</sup>Downgraded by one level for imprecision: confidence interval was wide or crossed assumed threshold of clinically important difference (or both).<br/> <sup>3</sup>Only one event in desmopressin group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Desmopressin versus placebo for men with nocturia (intermediate term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/full#CD012059-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012059-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Desmopressin versus behaviour modifications for men with nocturia (short term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> men with nocturia </p> <p><b>Setting:</b> likely outpatient </p> <p><b>Intervention:</b> desmopressin </p> <p><b>Control:</b> fluid restriction during nighttime </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with behaviour modification</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk difference with desmopressin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of nocturnal voids</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major adverse events</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of first sleep episode</b><br/> assessed with: not reported<br/> follow‐up: mean 2 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean duration of first sleep episode was 150 minutes.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 90 minutes higher<br/> (1.95 higher to 178.05 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first void</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor adverse events</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment withdrawal due to adverse event</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for study limitations: unclear risk of bias in almost all domains in the included study.<br/> <sup>2</sup>Downgraded by one level for imprecision: confidence interval crossed assumed threshold of clinically important difference. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Desmopressin versus behaviour modifications for men with nocturia (short term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/full#CD012059-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012059-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Desmopressin versus alpha‐blocker for men with nocturia (short term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> men with nocturia </p> <p><b>Setting:</b> likely outpatient </p> <p><b>Intervention:</b> desmopressin </p> <p><b>Control:</b> alpha‐blocker </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with alpha‐blocker</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk difference with desmopressin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of nocturnal voids</b><br/> assessed with: voiding diary<br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of nocturnal voids was 1.2 voids.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.3 voids more<br/> (0.2 fewer to 0.8 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><br/> assessed with: IPSS and N‐QoL<br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean quality of life was 1.8 bothersome.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0<br/> (0.35 lower to 0.35 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major adverse events</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of first sleep episode</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first void</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Minor adverse events</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/> (0.07 to 15.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 more per 1000<br/> (58 fewer to 911 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawal due to adverse event</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IPSS:</b> International Prostate Symptom Score; <b>MD:</b> mean difference; <b>N‐QoL:</b> Nocturia‐Quality of Life questionnaire; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for study limitations: unclear or high risk of bias for one or more domains in the included study.<br/> <sup>2</sup>Downgraded by one level for imprecision: no event in either group.<br/> <sup>3</sup>Downgraded by two levels for imprecision: confidence interval was wide and crossed assumed threshold of clinically important difference. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Desmopressin versus alpha‐blocker for men with nocturia (short term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/full#CD012059-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012059-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Desmopressin plus alpha‐blocker versus alpha‐blocker for men with nocturia (short term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> men with nocturia </p> <p><b>Setting:</b> likely outpatient </p> <p><b>Intervention:</b> desmopressin + alpha‐blocker </p> <p><b>Control:</b> alpha‐blocker alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with alpha‐blocker</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk difference with desmopressin + alpha‐blocker</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of nocturnal voids</b> </p> <p>assessed with: voiding diary<br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>341<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of nocturnal voids ranged from 1.68 to 2.6.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.47 voids fewer<br/> (0.73 fewer to 0.21 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p>assessed with: IPSS and N‐QoL<br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>341<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean quality of life ranged from 1.53 to 4.4.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.29 lower<br/> (0.51 lower to 0.07 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major adverse events</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>402<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.30<br/> (0.01 to 7.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 fewer per 1000<br/> (5 fewer to 32 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of first sleep episode</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first void</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Minor adverse events</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>402<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.60<br/> (0.15 to 16.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 more per 1000<br/> (68 fewer to 1000 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawal due to adverse event</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>402<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.84<br/> (0.46 to 17.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 more per 1000<br/> (3 fewer to 83 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IPSS:</b> International Prostate Symptom Score; <b>MD:</b> mean difference; <b>N‐QoL:</b> Nocturia‐Quality of Life questionnaire; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for study limitations: unclear or high risk of bias for one or more domains among the included studies.<br/> <sup>2</sup>Downgraded by one level for imprecision: no event or very rare event resulting in wide confidence interval.<br/> <sup>3</sup>Downgraded by two level for imprecision: confidence interval was wide and crossed assumed threshold of clinically important difference. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Desmopressin plus alpha‐blocker versus alpha‐blocker for men with nocturia (short term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/full#CD012059-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012059-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Desmopressin plus alpha‐blocker versus alpha‐blocker plus anticholinergic for men with nocturia (short term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> men with nocturia </p> <p><b>Setting:</b> likely outpatient </p> <p><b>Intervention:</b> desmopressin + alpha‐blocker </p> <p><b>Control:</b> anticholinergic + alpha‐blocker </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with alpha‐blocker + anticholinergic</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk difference with desmopressin + alpha‐blocker</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of nocturnal voids</b><br/> assessed with: voiding diary<br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>405<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of nocturnal voids was 6.97 voids.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.43 voids fewer<br/> (0.97 fewer to 0.11 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major adverse events</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>427<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of first sleep episode</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first void</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Minor adverse events</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>427<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.22<br/> (0.05 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 fewer per 1000<br/> (43 fewer to 1 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawal due to adverse event</b><br/> follow‐up: range 1 to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>427<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.22<br/> (0.05 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 fewer per 1000<br/> (43 fewer to 1 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for study limitations: unclear risk of bias for one or more domains in the included study.<br/> <sup>2</sup>Downgraded by one level for imprecision: no event in either group.<br/> <sup>3</sup>Downgraded by one level for imprecision: confidence interval crossed assumed threshold of clinically important difference. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Desmopressin plus alpha‐blocker versus alpha‐blocker plus anticholinergic for men with nocturia (short term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/full#CD012059-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012059-tbl-0007"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial period</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Description of participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of intervention<br/> (duration of follow‐up)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] ">Ahmed 2015a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient/Egypt</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2011 to 2014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>People with LUTS/BPH aged ≥ 50 years with nocturia (≥ 2 voids/night), nocturnal polyuria (nocturnal urine volume &gt; 30% of 24‐hour urine volume) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin 60 μg ODT + tamsulosin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: tamsulosin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0002" title="CannonA , CarterPG , McConnellAA , AbramsP . Desmopressin in the treatment of nocturnal polyuria in the male. BJU International1999;84(1):20‐4. [PUBMED: 10444118 ] ">Cannon 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged &gt; 50 years with nocturnal polyuria (using 48‐hour inpatient monitoring or 1‐week frequency volume chart) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin nasal spray 20 μg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] ">Ceylan 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient/Turkey</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with advanced age, complaints of LUTS and nocturia (≥ 3 times/night)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin nasal spray 20 μg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: doxazosin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '>Kim 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre/South Korea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged 40 to 65 years with LUTS (IPSS &gt; 13), nocturia (≥ 2 episodes/night), and nocturnal polyuria (NPI &gt; 33%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin 0.2 mg oral + alpha‐blocker</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + alpha‐blocker</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] ">Koca 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient/Turkey</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged 50 to 70 years with LUTS and nocturia (≥ 2/night)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin 0.2 mg oral with alfuzosin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: alfuzosin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] ">Mattiasson 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre/Denmark,<br/> Sweden, Netherlands, the UK, and the USA </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged ≥ 18 years with nocturia (2 voids/night, nocturia index scores &gt; 1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin 0.1 mg/0.2 mg/0.4 mg oral; dose titration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] ">Rezakhaniha 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient/single centre/Iran</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2008 to 2009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Older men (mean age about 63 to 64 years) with voiding ≥ 2/night</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin 0.1 mg oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals</a><a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre/USA and Canada</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men or women aged ≥ 50 years with nocturia (≥ 2 nocturic episodes/night)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin nasal spray 0.75 μg, 1.0 μg, or 1.5 μg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] ">Shin 2014a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>South Korea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010 to 2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged ≥ 50 years with LUTS due to bladder outlet obstruction (Q<sub>max</sub> ≤ 15 mL/second, IPSS ≥ 14) and nocturia (≥ 1 void/night) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin 0.2 mg oral + tamsulosin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: solifenacin + tamsulosin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] ">Wang 2011a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single centre/Taiwan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2007 to 2009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged ≥ 65 years with BPH (IPSS &gt; 13), nocturia (≥ 2 voids/night), and nocturnal polyuria (nocturnal urine volume &gt; 30%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin 0.1 mg oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0011" title="WangW , ChenS . Low dose oral desmopressin in treatment of nocturia in elderly men. Urology2012;80(3 Suppl):S117. [DOI: 10.1016/S0090‐4295(12)00880‐1] ">Wang 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient/single centre/China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2009 to 2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Older men (age not reported)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin 0.1 mg oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre/Canada and the USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2007 to 2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men and women aged ≥ 18 years with nocturia (≥ 2 voids/night)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin 10 µg, 25 µg, 50 µg, or 100 µg ODT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] ">Weiss 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre/Canada and the USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010 to 2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged ≥ 18 years with nocturia (≥ 2 voids/night)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin 50 μg, 75 µg ODT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre/Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010 to 2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men and women aged 55 to 75 years with nocturia (≥ 2 voids/night)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin 10 µg, 25 µg, 50 µg, or 100 µg ODT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>BPH: benign prostatic hyperplasia; C: comparator; I: intervention; IPSS: International Prostate Symptom Score; LUTS: lower urinary tract symptoms; NPI: nocturnal polyuria index; NR: not reported; ODT: orally disintegrating tablet; Q<sub>max</sub>: maximum flow rate. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/full#CD012059-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012059-tbl-0008"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participant disposition</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sample size</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Screened/eligible<br/> (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised<br/> (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ITT<br/> (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analysed<br/> (n: total/male)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Finishing trial<br/> (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised finishing trial<br/> (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up<br/> (extended follow‐up)<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012059-bbs2-0001" title="AhmedAF , MaaroufA , ShahinA , ShalabyE , GhobishA . The impact of adding low dose oral desmopressin to tamsulosin therapy for treatment of nocturia secondary to benign prostatic hyperplasia. Journal of Urology2014;191(4 Suppl):e667. [DOI: 10.1016/j.juro.2014.02.1840] AhmedAF , MaaroufA , ShalabyE , GabrAH , ShahinA , GhobishA . The impact of adding low‐dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology2015;33(5):649‐57. [DOI: 10.1007/s00345‐014‐1378‐2] "><b>Ahmed 2015a</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin + tamsulosin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>397/273</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: tamsulosin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>273</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012059-bbs2-0002" title="CannonA , CarterPG , McConnellAA , AbramsP . Desmopressin in the treatment of nocturnal polyuria in the male. BJU International1999;84(1):20‐4. [PUBMED: 10444118 ] "><b>Cannon 1999</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐/‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>8 weeks (cross‐over study design)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012059-bbs2-0003" title="CeylanC , CeylanT , DoluogluOG , YukselS , AgrasK . Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urology Journal2013;10(3):993‐8. [PUBMED: 24078508 ] "><b>Ceylan 2013</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>84/31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: doxazosin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012059-bbs2-0004" title='ChoKJ , LeeZZ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin "add‐on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo‐controlled study. European Urology Supplements2016;15(3):e543. [DOI: 10.1016/S1569‐9056(16)60545‐6] KCT0000271 . Efficacy and safety of desmopressin in men with persistent nocturia under alpha blocker monotherapy. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1541 (first received 2 September 2009). KimJC , ChoKJ , LeeJG , SeoJT , KimDY , OhSJ , et al. Efficacy and safety of desmopressin add‐on therapy for men with persistent nocturia on α‐blocker monotherapy for lower urinary tract symptoms: a randomized, double‐blind, placebo controlled study. Journal of Urology2017;197(2):459‐64. [PUBMED: 27622611 ] '><b>Kim 2017</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin + alpha‐blocker</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>121/109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>8 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + alpha‐blocker</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012059-bbs2-0005" title="KocaO , KelesM , GunesM , OzturkM , AkyuzM , KaramanMI . Desmopressin in the treatment of nocturia with BPH. Turkish Journal of Urology2012;38(1):29‐31. [DOI: 10.5152/tud.2012.006] "><b>Koca 2012</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin + alfuzosin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐/49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: alfuzosin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012059-bbs2-0006" title="AbramsP , WeissJ , MattiassonA , KerrebroeckP , WalterS , RobertsonG , et al. The efficacy and safety of oral desmopressin in the treatment of nocturia in men. Neurourology and Urodynamics2001;20(4):456‐7. MattiassonA , AbramsP , VanKerrebroeckP , WalterS , WeissJ . Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU International2002;89(9):855‐62. [PUBMED: 12010228 ] "><b>Mattiasson 2002</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>341/224</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012059-bbs2-0007" title="RezakhanihaB , ArianpourN , SiroosbakhatS . Efficacy of desmopressin in treatment of nocturia in elderly men. Journal of Research in Medical Sciences2011;16(4):516‐23. [PUBMED: 22091268] "><b>Rezakhaniha 2011</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>93/60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>8 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD012059-bbs2-0008" title="KaminetskyJ , WeinA , DmochowskiR , HerschkowitzS , ChengM , AbramsS , et al. A randomized, double‐blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. Journal of Urology2016;195(4 Suppl):e969. [DOI: 10.1016/j.juro.2016.02.1698] MacDiarmidS , DmochowskiR , AbramsS , ChengM , FeinS , WeinA . Efficacy/safety of SER120 nasal spray in nocturia patients ≥ 65 years: a pooled analysis from two randomized, placebo controlled phase 3 trials. Journal of the American Geriatrics Society2017;65(Suppl 1):S47‐8. [DOI: 10.1111/jgs.14915] NCT00937378 . Treatment of patients with nocturia (non‐PK study). clinicaltrials.gov/ct2/show/NCT00937378 (date first received 1 September 2017). NCT00937859 . Treatment of patients with nocturia. clinicaltrials.gov/ct2/show/NCT00937859 (date first received 1 September 2017). NCT01357356 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia. clinicaltrials.gov/ct2/show/NCT01357356 (accessed 1 September 2017). NCT01900704 . Multicenter study to investigate SER120 nasal spray formulations in patients with nocturia ‐ DB4 (DB4). clinicaltrials.gov/ct2/show/NCT01900704 (accessed 1 September 2017). RovnerES , BennettJB , AbramsS , KhalafKM , ChengL , FeinS , et al. Improvement in patient‐reported treatment benefit and health‐related quality of life following treatment with SER120 among patients with nocturia. Neurourology and Urodynamics2017;36(Suppl 1):S71. [DOI: 10.1002@nau.23228] SerenityPharmaceuticals . SER120 nasal spray advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM525331.pdf (accessed 30 August 2017). SussmanD , KaminetskyJ , EfrosM , MacDiarmidS , AbramsS , WengE , et al. SER120 nasal spray is effective in patients with nocturia irrespective of etiology: a pooled analysis of two randomized, placebo controlled phase 3 trials. Journal of Urology2017;197(4 Suppl):e507. [DOI: 10.1016/j.juro.2017.02.1211] SussmanDO , KaminetskyJC , EfrosMD , MacDiarmidSA , AbramsS , WengE , et al. SER120 nasal spray is effective for the treatment of nocturia in patients regardless of etiology: a pooled analysis of two randomized, placebo‐controlled phase 3 trials. Neurourology and Urodynamics2017;36(Suppl 1):S153‐4. [DOI: 10.1002/nau.23228] ">Serenity Pharmaceuticals 2016</a><b><sup>2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: desmopressin 0.75 μg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3565/1707</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>448</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>448/252</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>401</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: desmopressin 1.0 μg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183/109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I3: desmopressin 1.5 μg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>452</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>439</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>439/251</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>387</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>446</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>446/258</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>408</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1556</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1516</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1516/870</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1359</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012059-bbs2-0009" title="LeeS , ShinY , KimJ , ZhangL , ZhaoC , KimY , et al. Twelve‐week, prospective, open label, randomized trial for the effect of anticholinergic agent or antidiuretic agent as add‐on therapy to alpha‐blocker for lower urinary tract symptoms. Urology2014;84(4 Suppl):S226. [DOI: 10.1016/S0090‐4295(14)01020‐6] ShinYS , ZhangLT , ZhaoC , KimYG , ParkJK . Twelve‐week, prospective, open‐label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add‐on therapy to an alpha‐blocker for lower urinary tract symptoms. Clinical Interventions in Aging2014;10(9):1021‐30. [PUBMED: 25031529] "><b>Shin 2014a</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin + tamsulosin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>435/427</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>8 weeks (cross‐over study design)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: tamsulosin + solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>209</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>427</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>427</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>427</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>405</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012059-bbs2-0010" title="WangCJ , LinYN , HuangSW , ChangCH . Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double‐blind, placebo controlled, randomized study. Journal of Urology2011;185(1):219‐23. [DOI: 10.1016/j.juro.2010.08.095] "><b>Wang 2011a</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐/136</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012059-bbs2-0011" title="WangW , ChenS . Low dose oral desmopressin in treatment of nocturia in elderly men. Urology2012;80(3 Suppl):S117. [DOI: 10.1016/S0090‐4295(12)00880‐1] "><b>Wang 2012</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: desmopressin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐/60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>8 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD012059-bbs2-0012" title='NCT00477490 . Efficacy and safety of desmopressin melt for the treatment of nocturia. clinicaltrials.gov/ct2/show/study/NCT00477490 (accessed 30 August 2017). NCT00615836 . An extension study investigating the efficacy and safety of a fast‐dissolving ("melt") formulation of desmopressin for the treatment of nocturia in adults. clinicaltrials.gov/ct2/show/study/NCT00615836 (accessed 30 August 2017). WeissJ , ZinnerN , DaneshgariF , KleinB , NorgaardJP , Ancoli‐IsraelS . Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia and prolongs undisturbed sleep in patients with nocturia: results of a randomized placebo‐controlled study. International Urogynecology Journal and Pelvic Floor Dysfunction2010;21(1 Suppl):S285‐28. [DOI: 10.1007/s00192‐010‐1192‐3] WeissJP , SnyderJA , EllisonWT , BelkoffLH , KleinBM . Fast‐dissolving desmopressin (Melt) is well tolerated in nocturia: results of a randomized, placebo‐controlled study. Journal of Urology2010;183(4 Suppl):e589‐90. [DOI: 10.1016/j.juro.2010.02.1279] WeissJP , ZinnerNR , KleinBM , NorgaardJP . Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double‐blind, placebo‐controlled trial. Neurourology and Urodynamics2012;31(4):441‐7. [DOI: 10.1002/nau.22243] '>Weiss 2012a</a><b><sup>2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: desmopressin 10 µg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>1412/799</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155/82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>4 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: desmopressin 25 µg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152/87</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I3: desmopressin 50 µg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148/77</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I4: desmopressin 100 µg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146/80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156/90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>799</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>757</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>757/416</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>710</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012059-bbs2-0013" title="NCT01262456 . Investigation of the superiority effect of orally disintegrating desmopressin tablets to placebo in terms of night voids reduction in nocturia adult male patients. clinicaltrials.gov/ct2/show/NCT01262456 (date first received 30 August 2017). WeissJP , HerschornS , AlbeiCD , van derMeulenEA . Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double‐blind, placebo controlled, parallel group study. Journal of Urology2013;190(3):965‐72. [DOI: 10.1016/j.juro.2012.12.112] "><b>Weiss 2013</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: desmopressin 50 µg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>1013/395</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: desmopressin 75 µg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>395</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>385</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>385</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>323</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD012059-bbs2-0014" title="NCT01184859 . Comparative trial to investigate the dose‐response of 4 different dose levels of Minirin Melt and placebo (NOC). clinicaltrials.gov/ct2/show/study/NCT01184859 (date first received 1 September 2017). YamaguchiO , NishizawaO , JuulKV , NorgaardJP . Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial. BJU International2013;111(3):474‐84. [DOI: 10.1111/j.1464‐410X.2012.11547.x] ">Yamaguchi 2013</a><b><sup>2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: desmopressin 10 µg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>177/139</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: desmopressin 25 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I3: desmopressin 50 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I4: desmopressin 100 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112/54</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Overall total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Men</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2966</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="3" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1045</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4195</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4011</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>‐ denotes not reported; C: comparator; I: intervention; ITT: intention‐to‐treat; n: number of participants. </p> <p><sup>1</sup>Follow‐up under randomised conditions until end of trial or if not available, duration of intervention; extended follow‐up refers to follow‐up of participants once the original study was terminated as specified in the power calculation.<br/> <sup>2</sup>Study included men and women. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participant disposition</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/full#CD012059-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012059-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Desmopressin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of nocturnal voids (short term) (subgroup route) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.61 [‐0.96, ‐0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Intranasal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>870</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.34, ‐0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Sublingual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐0.71, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.14 [‐1.41, ‐0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of nocturnal voids (intermediate term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.85 [‐1.17, ‐0.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Major adverse events (short term) (subgroup route and dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.10, 9.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Sublingual/low dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>385</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.53 [0.73, 8.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Oral/high dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Major adverse events (intermediate term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [0.13, 73.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Duration of first sleep episode (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>54.61 [13.97, 95.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Duration of first sleep episode (intermediate term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.40 [11.60, 25.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Time to first void (short term) [minutes] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>40.8 [17.07, 64.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Minor adverse events (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>594</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.67, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Minor adverse events (intermediate term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.49, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Treatment withdrawal due to adverse event (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>614</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.56, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Treatment withdrawal due to adverse event (intermediate term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [0.13, 73.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Number of nocturnal voids (short term) (subgroup dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.65 [‐0.98, ‐0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Very low dose (≤ 1.5 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>870</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.34, ‐0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Low dose (&lt; 100 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>711</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.33 [‐0.72, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 High dose (≥ 100 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.03 [‐1.41, ‐0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Number of nocturnal voids (short term) (subgroup nocturnal polyuria) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.61 [‐0.96, ‐0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Men with nocturia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1867</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.73, ‐0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Men with nocturia and nocturnal polyuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.28 [‐1.64, ‐0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Number of nocturnal voids (short term) (sensitivity run‐in period) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.66 [‐1.17, ‐0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Major adverse events (short term) (sensitivity run‐in period) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>385</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.53 [0.73, 8.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Number of nocturnal voids (short term) (sensitivity clinical dosage) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.76 [‐1.15, ‐0.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Major adverse events (short term) (sensitivity clinical dosage) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.10, 9.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Sublingual/low dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.67 [0.71, 10.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Oral/high dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.37]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Desmopressin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012059-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Desmopressin versus behaviour modification</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Duration of first sleep episode (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>90.0 [1.95, 178.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Desmopressin versus behaviour modification</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012059-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Desmopressin versus alpha‐blocker</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of nocturnal voids (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.20, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Quality of life (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.35, 0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Major adverse events (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Minor adverse events (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.07, 15.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Treatment withdrawal due to adverse event (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Desmopressin versus alpha‐blocker</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012059-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Desmopressin plus alpha‐blocker versus alpha‐blocker</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of nocturnal voids (short term) (subgroup route and dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.47 [‐0.73, ‐0.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Sublingual/low dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.66 [‐0.90, ‐0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Oral/high dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.60, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of nocturnal voids (short term) (subgroup nocturnal polyuria) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.47 [‐0.73, ‐0.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Men with nocturia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.74, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Men with nocturia and nocturnal polyuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐0.86, ‐0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Quality of life (short term) (subgroup route and dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐0.51, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Sublingual/low dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.49, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Oral/high dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.44 [‐0.85, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Quality of life (short term) (subgroup nocturnal polyuria) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐0.51, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Men with nocturia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.84, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Men with nocturia and nocturnal polyuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.34 [‐0.67, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Major adverse events (short term) (subgroup route and dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.01, 7.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Sublingual/low dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Oral/high dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.01, 7.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Major adverse events (short term) (subgroup nocturnal polyuria) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.01, 7.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Men with nocturia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Men with nocturia and nocturnal polyuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.01, 7.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Minor adverse events (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [0.15, 16.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Treatment withdrawal due to adverse event (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [0.46, 17.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Desmopressin plus alpha‐blocker versus alpha‐blocker</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012059-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Desmopressin plus alpha‐blocker versus alpha‐blocker plus anticholinergic</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of nocturnal voids (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.43 [‐0.97, 0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Major adverse events (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Minor adverse events (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.05, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Treatment withdrawal due to adverse event (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.05, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Desmopressin plus alpha‐blocker versus alpha‐blocker plus anticholinergic</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012059.pub2/references#CD012059-tbl-0013">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012059.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012059-note-0002">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012059-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012059-note-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD012059-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012059-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012059\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012059\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012059\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012059\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012059\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012059\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012059\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012059\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012059\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012059\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012059\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012059\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012059\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012059\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012059\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012059\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012059\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012059\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=z6k50IFd&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012059.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012059.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012059.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012059.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012059.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714947401"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012059.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714947405"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012059.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7b1d0d359368',t:'MTc0MDcxNDk0Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 